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Characterization of The Roles of CARMA3 and BCL10 in Virus-Triggered RIGI/MAVS Signaling Pathway
Zhicheng Zhou, M.S.
Advisory Professor: Xin Lin, Ph.D.
ABSTRACT
After RNA virus infection, the innate immunity utilizes RIG-I family of receptors in the
cytoplasm to initiate the production of type-I IFNs and proinflammatory cytokines by mitochondrial
protein MAVS, which forms a prion-like structure to recruit TBK1and IKK complex to activate IRF3
and NF-κB, respectively. Herein, we revealed the important roles of CARMA3 and BCL10 in RIGI/MAVS signaling pathway for the first time. CARMA3 or BCL10 deficient cells exhibited partially
defective NF-κB activation but hyperactivation of TBK1-IRF3 signaling pathway upon ssRNA virus
infection. It led to less production of IL6 but more production of type I IFNs and resulted in
CARMA3-deficient mice more resistant to virus infection, including VSV and H1N1 influenza virus.
Mechanistic studies showed that CARMA3 and BCL10 physically interacted with MAVS and
directly regulated MAVS aggregation. Overexpression of CARMA3 and BCL10 inhibited MAVS
aggregation. Consistently, MAVS aggregation more easily occurred in CARMA3 deficient cells after
VSV infection. VSV induced the cleavage of CARMA3 and led to more MAVS aggregation. These
novel findings not only identified the important role of CARMA3 and BCL10 during influenza virus
infection, which may provide the new target for future therapeutic interference but also revealed
molecular mechanism by which CARMA3 and BCL10 orchestrated the NF-κB and IRF3 activation
to balance the production of type I IFNs and proinflammatory cytokines.

xii

CHAPTER 1: INTRODUCTION

The essential event of immunology system is to recognize the microbial pathology and to
initiate the appropriate immune responses to fight against invasion pathology. In this process,
pattern recognition receptors (PRRs) recognize small molecular motifs conserved within a
class of microbes, also known as pathogen-associated molecular patterns(PAMPs) and
activate a serious of signaling pathways to initiate innate immunity(Janeway 2013). The
well-characterized mammal PRRs include membrane-associated Toll-like receptors(TLRs),
c-type lectin receptors(CLRs), cytosolic receptors such as NOD-like receptors(NLRs), RIG-I
like receptors(RIRs) and AIM2-like receptors (ALRs)(Kawai and Akira 2011). Since our
research mainly focused on two RNA virus, influenza A virus and vesicular stomatitis
Indiana virus (VSV), the following chapter mainly describes the receptors and their
downstream signaling pathways that are involved in RNA virus detection and clearance.

1.1 Toll-like receptors

TLRs are the first PRRs to be characterized. They comprise a large family of membranebound receptors, which are named from their similarity to the toll protein of drosophila
identified in 1985 (Hansson and Edfeldt 2005). The vertebrate TLR family consists of 13
members, including TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, TLR9, TLR10,
TLR11, TLR12 and TLR13, which are characterized by extracellular domain containing
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leucine-rich repeats (LRRs), a transmembrane region and a cytoplasmic Toll/IL-1 receptor
(TIR) domain(Lester and Li 2014). Each receptor senses the PAMPs derived from diverse
microbes, including bacterial cell wall components such as lipoproteins(for TLR1, TLR2,
and TLR6), lipopolysaccharide(LPS)(for TLR4), as well as bacterial flagellin(for TLR5),
bacterial DNA(for TLR9),virus-derived double stranded(dsRNA)( for TLR3) and singlestranded(ssRNA)(forTLR7 and TLR8)(Table 1)(Akira, Uematsu et al. 2006).
Upon ligand recognition, TLRs recruit a serious of adaptor proteins to activate
downstream signaling pathways. Based on different adapters, these signaling pathways can
be divided into two types, myeloid differentiation primary response gene (88) (MyD88)- and
the TIR-domain containing adaptor inducing IFN-β (TRIF)-dependent pathways. TLR3 and
TLR4 recruit TRIF, while other TLRs with the exception of TLR3 utilize MyD88. Through
these adapters, TLRs trigger the activation of nuclear factor kappa-light-chain-enhancer of
activated B cells(NF-κB)/ the activator protein 1 (AP-1) and distinct IFN regulatory factor -3
and -7(IRF3/7) pathways to orchestrate innate and adaptive immune responses against the
invasion of diverse pathogens(Kawai and Akira 2011).
TLRs play an important role in antivirus immune response. Viruses depend on the host
cells to complete their replication cycle. During the virus life cycle, the virus-derived PAMPs
are recognized by TLRs. The role of TLRs is to trigger the production of IFN (IFN) and/or
proinflammatory cytokines. It has been shown that TLR3, TLR7/TLR8/TLR9, TLR4 and
TLR2 have an important impact on antivirus innate immunity(Fig.1)(Lester and Li 2014).
TLR3 is located in endosome and is the first well-studied nucleotide-sensing TLR
(Alexopoulou, Holt et al. 2001). TLR3 recognizes virus-derived dsRNA, a molecular
2

signature of many RNA viruses. Polyriboinosinic:polyribocytidylic acid (poly(I:C)),a
synthetic dsRNA analog, also triggers the activation of TLR3-dependent signaling pathways.
The in vitro binding assay revealed that TLR3 ectodomain was capable of interacting with
the dsRNA with the length of 40–50 bps long, while the TLR3 signaling was activated by
ligand with the length of 90bps or longer(Leonard, Ghirlando et al. 2008). As a PAMP,
dsRNA itself constitutes virus genome or is generated as a replicative intermediate during
virus life cycle. Therefore, TLR3 recognizes multiple types of viruses, including dsRNA
virus, ssRNA virus and DNA virus. Upon viral dsRNA recognition, TLR3 undergoes
tyrosine phosphorylation on Tyr858 and Tyr759 in its cytoplasmic domain (Lee, Xu et al.
2012, Yamashita, Chattopadhyay et al. 2012). Upon activation, the receptors recruit the
TRIF- TNF receptor associated factor 6(TRAF6) - receptor-interacting protein 1(RIP1)
complex, which leads to the activation of transforming growth factor beta activated kinase
1(TAK1) and subsequently the classical IκB kinase (IKK) complex (Sato, Sugiyama et al.
2003, Jiang, Mak et al. 2004, Meylan, Burns et al. 2004). Then, the activated IKK complex
phosphorylates nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor,
alpha (IκBα) on its serine 32 and 34 and causes it to be degraded by the proteasome, which
will release NF-κB dimmers. The free NF-κB dimmers enter the nucleus and turn on the
transcription of the specific genes with the κB site in the promoter (Kawai and Akira 2011).
On the other hand, TRIF associates with TRAF3 to activate the noncanonical IKK kinases,
TBK1 and/or IKKε. The activated TBK1 and IKKε phosphorylate and activate IRF3 and
IRF7. The phosphorylated IRF3 and IRF7 undergo the dimerization and then go into the
nucleus to induce the production of type I and/or type III IFNs. These proinflmmatory
3

cytokines and IFNs serve as the first defense line against virus infection. Therefore, during
virus infection, any dysregulation of TLR3 singling results in severe outcomes. For example,
mice lacking TLR3 are hypersensitive to the infection of mouse cytomegalovirus (MCMV),
herpes simplex virus (HSV) 2, poliovirus, encephalomyocarditis virus (EMCV), coxsackie
virus B3 or B4, rotavirus etc., as it is evidenced by the significantly increased viral shedding
and decreased production of antiviral and proinflmmatory cytokines(Hoebe, Du et al. 2003,
Tabeta, Georgel et al. 2004, Herman, Ciancanelli et al. 2012). This in vivo evidence confirms
the importance of TLR3 in antivirus immune response.
Similar to TLR3, TLR7 and TLR8 are also located in endosome. They recognize GU-rich
and AU-rich ssRNA sequence of RNA viruses, including the human immunodeficiency
virus (HIV-1), VSV, sendai virus, coxsackie B virus, coronaviruses, flaviviruses, such as
HCV, dengue virus and WNV(Diebold, Kaisho et al. 2004, Heil, Hemmi et al. 2004, Lund,
Alexopoulou et al. 2004). In recognition of viral-derived ssRNA in endosome, TLR7 or
TLR8 utilizes MyD88-dependent pathways to activate NF-κB and IFN regulatory factor
(IRF7). More specifically, the TLR7 or TLR 8 recruits interleukin-1 receptor-associated
kinase (IRAK4), interleukin-1 receptor-associated kinase (IRAK1) and many E3 ubiquitin
ligases, such as TRAF6 and TRAF3, through MyD88. It leads to the activation of IKKa and
TAK1. TAK1 directly phosphorylates IKKβ in the IKK complex and subsequently activates
NF-κB signaling pathway. In parallel, IKKα and IRAK1 phosphorylate and activate IRF7,
resulting in the production of IFN alpha (Hemmi, Kaisho et al. 2002, Kawai, Sato et al. 2004,
Honda, Yanai et al. 2005). Also, the tissue distribution of TLR7 and TLR8 suggests their
important role in innate immunity. Different from TLR3 with wide tissue distribution ,
4

TLR7 is predominatly expressed in plasmacytoid dendritic cells (pDCs), B cells and
monocytes/macrophages, while TLR8 is only found in monocytes/macrophages and myeloid
dendritic cells(Lester and Li 2014).
TLR9 is another endocytic PRR, which recognizes unmethlated CpG motifs, a PAMP of
many bacterial and viral DNA. The unmethlate CpG is always found in microbial genomes
but rare in verterbrate genome, by which TLR9 can discriminate host DNA from microbederived DNA(Latz, Schoenemeyer et al. 2004). Besides, the intracellular localiztion of TLR9
decreases the risk responding to self DNA and developing autoimmune disease. TLR9 is
expressed in many immune cells including macrophage, B cells, myeloid dendritic cells,
classical dendritic cells(cDCs) and pDCs. Similar to TLR7 and TLR8, TLR9 utilizes
MyD88-dependent pathways to activate IRF7 and NF-κB. Mice with TLR9 deficiency are
hypersusceptible to many double-stranded DNA virus infection, including mouse
cytomegalovirus (MCMV), HSV 1 and HSV 2, and poxviruses(Lund, Sato et al. 2003, Krug,
Luker et al. 2004, Tabeta, Georgel et al. 2004).
Unlike endocytotic TLRs, TLR2 and TLR4 are located in cell membrane, which
recognize viral envelop proteins or viral proteins that are released to extracellular milieu. For
example, TLR2 recognizes the core and NS3 proteins of HCV, the glycoproteins B and H of
human cytomegalovirus, the glycoproteins, such as gH/gL and gB of HSV, the UTPase of
EBV and hemagglutinin(HA) protein of measles virus and nsp4 of rotavirus(Bieback, Lien et
al. 2002, Compton, Kurt-Jones et al. 2003, Boehme, Guerrero et al. 2006, Ariza, Glaser et al.
2009, Leoni, Gianni et al. 2012). TLR4 recognizes the VSV-G protein of VSV, the GP
protein of Ebola virus, the envelop protein of MMTV and so on (Georgel, Jiang et al. 2007,
5

Ariza, Glaser et al. 2009, Okumura, Pitha et al. 2010). After engagement of ligands, TLR2
and TLR4 activate downstream signal pathways in different manners. Specifically, TLR2
dimmerizes with other TLRs such as TLR1 or TLR6 on the cell membrane. Then, TLR2
initiates MyD88-dependent pathways to activate NF-κB. The role of TLR2 in IFN production
seems controversial, which may depend on the cells type and virus types. Different from
TLR2, TLR4 does not form a heterodimer with other TLRs. TLR4 signal on the cell
membrane is transduced via MyD88- and TRIF- dependent pathways. In TLR4 signaling,
the activation of early-phase NF-κB is linked to MyD88-dependent pathways, while the late
phase NF-κB and IRF3/7 are activated by TRIF-dependent pathways(Lester and Li 2014).
These TLRs sense diverse virus-derived PAMPs and constitute a powerful antiviral
innate immune system to quickly react to invading viruses(Lester and Li 2014).

1.2 RIG-I and MAVS signaling pathway

The innate immunity utilizes not only TLRs but also RIG-I- like family receptors (RLRs)
in the cytoplasmic compartments to detect viral infection. Upon activation, RIG-I initiates
distinct signaling pathways to produce type I IFN and other proinflmmatory cytokines (e.g.,
TNFα and IL-6), which quickly limit virus infection and activate the adaptive immune
system (Akira, Uematsu et al. 2006, Kawai and Akira 2006).
Previous studies have identified several RLR family members, including RIG-I,
melanoma differentiation associated gene 5(MDA5), and laboratory of genetics and
physiology 2(LGP2). All of the three RLRs are DExD/H box RNA helicases and share very
6

similar domains, including the central DExD/H box RNA helicase domain with ATPase
activity and the C‑terminal domain (CTD). Different from LGP2, RIG-I and MDA5 contain
the N‑terminal domain (NTD) consisting of tandem CASPASE activation and recruitment
domains (CARDs). Without CARD domains, LGP2 serves as a regulatory but not an
essential component in RIG-I/MDA5/mitochondrial antiviral-signaling protein (MAVS)
signaling pathway (Satoh, Kato et al. 2010).
These functional domains contribute to the overall function of a protein. Among RLRs
family proteins, only the structures of “active” and “silence” RIG-I have been well studied,
therefore, we will take RIG-I as an example to interpret the function of domains in RLRs
family proteins. In resting cells, the N-terminal CARD domains are bound to the central
helicase domain of the protein and thus, are not available for their function. After RNA virus
infection, the “free” CTD senses viral RNA and interacts with blunt-ended 5’pppdsRNA.Then, the CTD competes with the CARD domains to interact with central helicase
domain and release CARD domains. After that, the “free” CARD domains become
potentially available for downstream adaptors, for example, MAVS. RIG-I interacts with
MAVS through the CARD domains, which activates MAVS to form prion -like structure.
Then, the aggregated MAVS works as a platform in the mitochondrial to recruit the IKK and
TBK1 complex to activate NF-κB and IRF3 signaling pathways, respectively (Hou, Sun et al.
2011)(Fig. 2). Followed by ATP hydrolysis and phosphate release, the helicase domain no
longer interacts with the CTD but binds to the CARD domain again. It results in the
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dissociation of RIG-I from MAVS and stops the activation of signaling pathways (Zeng, Sun
et al. 2010, Kolakofsky, Kowalinski et al. 2012).
Although three RLRs share very similar protein structure, they do have some functional
difference. For example, RIG-I and MDA5 can recognize different RNA viruses. RIG-I is
essential for innate immunity to many ssRNA viruses, including influenza A and B virus,
NDV, Sendai virus (SeV), respiratory syncytial virus, measles virus, VSV, rabies virus, HCV
and Japanese encephalitis virus. After transcription of AT-rich DNA genome of DNA virus,
RIG-I can recognize some DNA viruses including adenovirus, HSV1, and EBV (Sumpter,
Loo et al. 2005, Hornung, Ellegast et al. 2006, Kato, Takeuchi et al. 2006, Samanta, Iwakiri
et al. 2006, Plumet, Herschke et al. 2007, Saito, Hirai et al. 2007, Loo, Fornek et al. 2008,
Ablasser, Bauernfeind et al. 2009, Chiu, Macmillan et al. 2009). Different from RIG-I,
MDA5 protects host from the infection of EMCV, Theiler’s virus, mengovirus, murine
norovirus, and murine hepatitis virus(Kato, Takeuchi et al. 2006, McCartney, Thackray et al.
2008, Roth-Cross, Bender et al. 2008). Recognition of different viruses suggests that RIG-I
and MDA can detect distinct features of RNA viruses. 5'-triphosphate RNA as well as short
(<2 kbp) dsRNAs is the ligand for RIG-I, while MDA5 can be activated by transfection of a
long (>2 kbp), synthetic dsRNA analog of artificial sequence, namely
polyinosinic:polycytidylic [poly(I:C)](Hornung, Ellegast et al. 2006). Additionally, LGP2 is
different from other family members. Without CARD domain, LGP2 cannot interact with
adaptor protein MAVS and thereby, play a negative role in regulating RIG-I and MDA5mediated antiviral response (Satoh, Kato et al. 2010).
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MAVS mediates antiviral response as an adapter protein for RLRs. MAVS was first
identified by the four independent labs almost at the same time in 2005. Therefore, MAVS is
also known as virus-induced signaling adapter (VISA), IFN-β promoter stimulator 1(IPS-1)
and CARD adapter inducing IFN beta (Cardif) (Kawai, Takahashi et al. 2005, Meylan,
Curran et al. 2005, Seth, Sun et al. 2005, Xu, Wang et al. 2005). Different from mice with
loss of RIG-I, MAVS-deficient mice were viable and fertile. However, the knock-out mice
fail to produce type I- IFN in response to poly (I:C) stimulation and increase mortality during
virus infection. It suggests the important role of MAVS in innate immunity against viral
infection (Sun, Sun et al. 2006). MAVS contains an N-terminal CARD followed by a
proline-rich region and a transmembrane domain (TMD). These domains together contribute
to the overall function of protein. The N-terminal CARD is important for MAVS interaction
with upstream RLRs. The prolin-rich region in MAVS is required for the recruitment of
many E3 ligases including TRAF2, TRAF5 and TRAF6. The TMD domain is important for
MAVS mitochondrial localization. Being activated, MAVS forms a prion-like structure in
the mitochondrial outer membrane and works as a platform to assembly a MAVS
signalosome including TRAF2, TRAF3, TRAF6, TRAF family member-associated NF-κB
activator (TANK), TNFR1-associated death domain protein (TRADD). The formation of a
MAVS signaling complex leads to the activation of NF-κB and IRF3 to produce proinflammation cytokines and type I IFNs. These secreted proteins become the first defense
line against virus infection(Fig. 2)(Jacobs and Coyne 2013).

1.3 IFN and antivirus response
9

After virus infection, host cells quickly releases IFNs, which provides the first defense
line against virus invasion (Colonna, Krug et al. 2002). The IFNs were firstly discovered at
the early 1950. It was found that virus-infected cells were resistant to the second virus
infection under some conditions. However, people did not identify the substrate or agent
responsible for this phenomenon at that time (Henle 1950). In 1957, Issacs and Lindenmann
coined the term “IFN” to describe the substrate secreted by the cells to interfere the virus
infection (Isaacs and Lindenmann 1957, Isaacs, Lindenmann et al. 1957). Twenty years later,
the IFNs were firstly purified from the medium of stimulated human white blood cells
(Cantell, Hirvonen et al. 1981, Cantell, Hirvonen et al. 1981). After the refinement of
purification schemes, it was found that IFN was not one but a family of different
proteins(Cantell, Hirvonen et al. 1981). Until now, more than 20 distinct IFNs have been
identified in animal, including humans(Schneider, Chevillotte et al. 2014).
IFNs belong to a large family of cytokines. After virus infection, IFNs produced by cells
are released into extracellular milieu, where they can be recognized by different IFN
receptors(Schneider, Chevillotte et al. 2014). Based on different receptors, the IFNs are
divided into three different classes, type I IFN, type II IFN and type III IFN. Type I IFN is
the largest group in IFN family, including IFNα, IFNβ, IFNε, IFNκ and IFNω in
humans(Schneider, Chevillotte et al. 2014). All type I IFN proteins are recognized by the
type I IFN heterodimeric receptors, which consist of IFNα receptors 1(IFNAR1) and IFNα
receptors 2 (IFNAR2). Type I IFN proteins can be produced by nearly all types of cells.
Consistently, IFN receptors are ubiquitously expressed. Wide tissue distribution of IFNs with
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their receptors suggests their important role in antiviral innate immunity(Schneider,
Chevillotte et al. 2014). Different from type I IFNs, there are only one type II IFN, IFNγ. In
the recognition of IFNγ, the type II IFN receptor forms a complex with interaction between
two IFNγ receptor 1(IFNGR1) subunits and two IFNγ receptor 2(IFNGR2), which results in
the activation of the receptors(Walter, Windsor et al. 1995). Although the type II IFN
receptor is expressed on the cell surface of all cell types, the IFNγ is only produced by the
cells of immune system and plays an important role in both innate and adaptive
immunity(McLaren and Ramji 2009, Zaidi and Merlino 2011). In 2003, the type III IFN class
was identified by two different groups (Kotenko, Gallagher et al. 2003, Sheppard,
Kindsvogel et al. 2003). Until now, four different members have been identified. They are
IFNL1, IFNL2, IFNL3 and IFNL4 (also known as IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4) (Fox,
Sheppard et al. 2009, Prokunina-Olsson, Muchmore et al. 2013). The structure of these
proteins is similar to the proteins of the IL-10 cytokine family. Therefore, the type III IFNs
bind to IL-10 receptor 2 with low-affinity. Additionally, the types III IFNs interact with type
III IFN receptor with high affinity and activate downstream signaling pathways(Fox,
Sheppard et al. 2009). Together, IFNs and their receptors constitute an immune system in
response to virus infection (Fig. 3).
Although distinct IFNs can be recognized by different receptors, they share janus kinases
(JAKs)- signal transducers and activators of transcription(STATs) signaling pathway to
increase the transcription of IFN-stimulated genes (ISGs)(Stark and Darnell 2012). In resting
cells, the JAKs interact with the cytoplasmic domain of each IFN receptor subunits in an
inactive form. Upon ligand stimulation, receptor chains undergo conformational change to
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bring the kinase domains of JAKs into close proximity, where JAK are autophosphorylated
and subsequently activated. Then, the “active” JAKs in turn phosphorylate the cytoplasmic
part of IFN receptors on some conserved tyrosine residues, which works as the docking sites
for STAT proteins. The Src homology domain2 (SH2) on STAT is responsible for STATreceptor interaction. The receptor-recruitment of STAT proteins is essential for
phosphorylation and activation of STAT proteins. After phosphorylation, STAT proteins
undergo conformational change and form a homo-(type II IFN) or heterodimer (type I and
type III IFN). Then, STAT dimmers are released from IFN receptors and enter the nucleus,
where they serve as transcriptional factor to drive expression of ISGs (Schindler, Shuai et al.
1992, Shuai, Schindler et al. 1992, Greenlund, Morales et al. 1995, Heim, Kerr et al. 1995,
Sekimoto, Imamoto et al. 1997, Melen, Kinnunen et al. 2001, Fagerlund, Melen et al. 2002,
McBride, Banninger et al. 2002, van Boxel-Dezaire, Rani et al. 2006) (Fig. 3).
ISGs are involved in a wide of cellular activities. They limit virus infection by directly
targeting proteins or functions involved in the virus life cycles. In absence of virus, ISGs are
kept in a low level. After virus infection, the induction of ISGs takes places through PRRstriggered signaling pathways to reinforce the IFN response and prime antiviral immune
response(Schneider, Chevillotte et al. 2014).
Virus relies on host cells to complete their life cycle, which includes cellular entry of
virus, translation and replication of viral genomes and viral shedding(Schneider, Chevillotte
et al. 2014). ISGs target these stages of viral life cycle through different mechanisms. For
example, the murine myxovirus resistance 1 and 2(Mx1 and Mx2) are two important ISGs
targeting the cellular entry of virus. Both of them are small guanosine
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triphosphatases(GTPase)(Schneider, Chevillotte et al. 2014). Mx1 traps uncoating of
ribonuclocapsids and thereby, interferes endocytic traffic of incoming virus particles (Gao,
von der Malsburg et al. 2010). In this way, MX1 prevents viral components from reaching
their cellular destination and inhibits the translation and replication of viral genome.
Similarly, MX2 inhibits the replication cycle of HIV-1 by preventing viral reversetranscribed genome from reaching its nuclear destination (Kane, Yadav et al. 2013). Another
set of ISGs inhibits viral replication and translation, such as the IFN-induced protein with
tetratricopeptide repeats (IFIT) family, the OAS-RNaseL pathway, PKR and zinc-finger
antiviral protein (ZAP) (Goff 2004, Kok and Jin 2013, Munir and Berg 2013). Furthermore,
many ISGs execute their inhibitory functions at the last stage of virus life cycle. Viperin and
tetberin are two good examples. Upon influenza or HIV infection, the amount of viperin was
induced, which affected plasma membrane fluidity through disrupting lipid rafts. The lipid
rafts with appropriate membrane fluidity is perquisite for influenza or HIV shedding. By
disrupting lipid rafts, viperin blocks virus shedding (Wang, Hinson et al. 2007, Nasr,
Maddocks et al. 2012). Different from viperin, tetberin directly traps virus particles on the
plasma membrane through utilizing two membrane anchors (Perez-Caballero, Zang et al.
2009).
Another important role of ISGs is to desensitize cellular IFN response. IFN response not
only renders cells resistance to virus infection but also triggers inflammation. Under some
conditions, the sustained IFN response leads to apoptosis. Therefore, in some cases, the
hyperactivation of IFN signaling pathway can cause severe outcomes. To return cellular
homeostasis, many ISGs reduce the activation of the JAK-STAT signaling pathway to
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negatively regulate IFN signal(Schneider, Chevillotte et al. 2014). Among them, suppressor
of cytokine signaling proteins (SOCS) and ubiquitin-specific peptidase 18(USP18) undergo
intensive investigation. SOCS directly interacts with IFN receptors or the JAK proteins and
serves as pseudosubstrates of the kinase. Therefore, it inhibits the activation of JAK-STAT
signaling pathway(Hong and Carmichael 2013). The induction of USP18 results in a more
sustained inhibition of IFN signaling. USP18 interacts with the cytoplasmic part of IFNα
receptor2 (IFNAR2), which leads to the conformational changes of the extracellular domain
of IFNAR2. It keeps the IFNAR from binding with IFNα and shut down the JAK-STAT
signaling cascade. In contrast, USP18 also interacts with IFNβ receptor but cannot inhibit
the signaling cascade, which may due to the IFNβ interact with its receptor with high affinity.
It seems that USP18 specifically inhibits IFNα signaling, since it does not interact with type
II and type III IFN receptors(Schneider, Chevillotte et al. 2014).
In sum, ISGs play an important role in regulating the antiviral immune responses and
keeping cellular homeostasis, which is important for the host cells to survival and control the
infection of pathogen.

1.4 NF-κB signaling pathway and CARMA family members

The prototype of NF-κB is referred as p65 and p50 heterodimer. They belong to a family
of transcription factors that regulate the transcription of various genes involved in diverse
cellular activities including inflammation, immune response, cell growth, apoptosis,
differentiation and etc. The NF-κB family has five members, which are NF-κB1 (p105/p50),
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NF-κB2 (p100/p52), RELA (p65), RELB and c-Rel. All NF-κB proteins contain Rel
homology domain (RHD) in their N-terminus, which plays an important role in NF-κB
protein’s dimerization and DNA binding. The difference among members lies in their
transcription domain. According to the presence of transcription domain, the NF-κB family
proteins are classified into two groups. The first group consists of RELA, RELB and c-Rel.
They contain a transactivation domain in their C-terminal and are synthesized as mature
proteins. The second group includes NF-κB1 and NF-κB2. They do not have a
transactivation domain but instead C-terminal ankyrin repeats. They are large precursors and
undergo processing through the ubiquitin/proteasome pathway to generate the mature
proteins, p50 and p52 respectively. This processing is to selectively degrade NF-κB1 and
NF-κB2’s C-terminal regions. (Hayden and Ghosh 2004, Natoli 2010).
Two distinct NF-κB signaling pathways have been characterized, namely the canonical
and non-canonical pathway. In the canonical NF-κB signaling pathway, in quiescence cells,
NF-κB dimmers are associated with IκB proteins that block the NF-κB nuclear localization
domains and thereby, preventing translocation of NF-κB into the nucleus. The canonical NFκB signaling pathway is activated by a wide variety of receptors, including receptors for
proinflammatory cytokines, such as tumor necrosis factor α (TNFα) and interleukin-1β (IL1β), TLRs, TCRs, growth factor receptors, such as epithelial growth factor receptor family
members, and G protein-coupled receptors (GPCR). Upon receipt of appropriate signals,
many signaling cascades are activated, leading to activation of the IκB kinase (IKK)
complex. Activation of the IKK complex results in IκBα phosphorylation at Ser32 and Ser36,
ubiquitination, and degradation, which frees the NF-κB dimers. Then, the free NF-κB
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dimmer translocates from the cytoplasm into the nucleus and facilitates transcription of its
target genes (Hayden and Ghosh 2004, Perkins 2007).
Different from the canonical NF-κB signaling pathways, the non-canonical NF-κB
signaling pathway is thought to mainly mediate the adaptive immune functions. The
activation of non-canonical NF-κB pathway relies on the stabilization of NF-κB inducing
kinase (NIK). In resting cells, NIK is constantly degraded in a TRAF3-dependent manner. In
brief, inhibitor of apoptosis (cIAP) proteins target NIK for ubiquitination and continuous
proteasomal degradation through tumour necrosis factor receptor associated factor 2 (TRAF2)
and TRAF3. TRAF3 serve as an adaptor that directly brings NIK to the TRAF2–cIAP
complex through TRAF3 interaction with TRAF2(Gyrd-Hansen and Meier 2010). Upon
receiving appropriate signals, TRAF3 undergoes K-48 linked ubiquitination and consequent
degradation, which frees NIK from its E3 complexes. Then, the NIK is stabilized and
activates its downstream kinase IKKα. The activated IKKα phosphorylates S866 and S870
on the NIK-responsive domain of p100. These two phosphorylation residues, S866 and S870
sites, serve as docking sites of the SCFβTrCP ubiquitin ligase complexes. The upstream lysine
(K) residue, K856, on p100 works as the ubiquitin acceptor site. The phosphorylation and
ubiquitination of p100 facilitate its proteasomal processing to p52 through the deletion of cterminal of p100(Oeckinghaus and Ghosh 2009). Then, p52 and RelB heterodimers enter the
nucleus and regulate the expression of genes, including cxcl12, cxcl13 and etc. These genes
play an important in B cell homeostasis and lymph node(Oeckinghaus and Ghosh 2009).
Recent studies have revealed the unexpected role of non-canonical NF-κB signaling
pathway in innate immunity (Jin, Hu et al. 2014). Mice and cells with genetic deficiencies in
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non-canonical NF-κB components produced more type I IFN upon dsRNA virus infection.
As a result, the mice and cells were more resistant to viral infection. Besides, the authors
found that the virus-induced activation of non-canonical NF-κB suppressed the recruitment
of a histone demethylase, JMJD2A and transcriptional factor RelA to the ifnβ promoter,
which play important role in the infβ transcription (Jin, Hu et al. 2014). In this way, noncanonical NF-κB signaling pathway works synergistically with canonical NF-κB signaling
pathway to regulate type I IFN induction and thus, is involved in host anti-virus response.
While there has been tremendous progress in revealing the NF-κB signaling pathways in
the context of different situations, it still remains to be seen what is the mechanistic details
regarding stimulation-specific activation of IKK complex. The scaffold complexes are
thought to serve as a platform in determining NF-κB activation in different context. Among
different scaffold proteins, members from Caspase Recruitment domain(CARD)- and
membrane-associated guanylate kinase-like domain-containing protein (CARMA) , play an
important role in regulating IKK activities(Blonska and Lin 2011).
CAMAR family has three members, CARMA1, CARMA2 and CARMA3, which are
encoded by different genes. They are conservative among different species and share very
similar structure homology. There is an N-terminal CARD domain, followed with a coiledcoil domain(C-C), a PDZ domain, an SH3 domain, and a the C-terminal guanylate kinaselike (GUK) domain in all family members. Each domain has its own unique function and
together contributes to overall protein functions. Since the functions of CARMA1 are well
studied, we will take CARMA1 as an example to introduce the function of domains located
in CARMA family proteins. Original study suggested that CARMA1 was required for T cell
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receptor (TCR)-induced NF-κB activation (Gaide, Favier et al. 2002, Wang, You et al. 2002,
Blonska and Lin 2011). In resting status, CARMA1 is kept in the inhibitory conformation.
Upon stimulation, CARMA1 is recruited into the immunological synapse through its
MAGUK domain and its adaptor protein known as adhesion and degranulation-promoting
adapter protein. In immunological synapse, PKCβ (in the B cells) or PKCθ (in the T cells)
can phosphorylate CARMA1 at the linker region between the C–C and PDZ domain, which
leads to the release of CARMA1 autoinhibition(Matsumoto, Wang et al. 2005, Sommer, Guo
et al. 2005). Then, the “activated” CARMA1 undergoes auto-oligomerization and recruits its
partner B-cell lymphoma (Bcl10) to form CARMA1/Bcl10 complex (Jiang and Lin 2012). In
the complex, CARMA1 serves as nucleator of Bcl10 polymerization. Then, CARMA1/Bcl10
complex further interacts with paraCASPASE mucosa-associated lymphoid tissue lymphoma
translocation protein 1(MALT1) to form CBM signalosome and regulates NF-κB activities
(Qiao, Yang et al. 2013).
Although CARMA proteins shared very similar domains, they have different tissue
distribution. CARMA1 is only expressed in the hematopoietic tissues, whereas CARMA3 is
expressed in the non-hematopoietic tissues and CARMA2 is expressed in the placenta, skin
and mucosal tissues (Bertin, Wang et al. 2001, Gaide, Martinon et al. 2001, McAllisterLucas, Inohara et al. 2001, Wang, Guo et al. 2001). The distinct tissue distribution of
CARMA proteins indicates that they may regulate NF-κB signaling pathway by forming the
complex with BCL10 and MALT1 in a similar manner but in different tissues. Consistent
with this concept, BCL10 and MALT1 are expressed in all tissues(Jiang and Lin 2012).
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Although the role of CARMA1 in NF-κB signaling pathway had been intensively studied,
the function of other CARMA proteins has not been well characterized. Original studies
showed that CARMA3 interacted with Bcl10 and activated NF-κB, when they are
overexpressed in the mammalian cells (Wang, Guo et al. 2001). The following studies mainly
focus on the role of CARMA3 in some GPCRs signaling pathways. GPCRs are also known
as seven-transmembrane domain receptors (7TM receptors), serpentine receptors, and G
protein-linked receptors (GPLR), which comprises the largest integral membrane protein
family encoded in the human genome with nearly 1000 members. Many of them can activate
NF-κB through PKCs(Jiang and Lin 2012). Since CARMA1works downstream of PKC in
antigen receptor-induced NF-κB activation, it is reasonable to hypothesize that CARMA3
plays a similar role downstream of PKC and is involved in some GPCR-induced NF-κB
activation. Indeed, the researchers showed there were the defects of IKK and NF-κB
activation in CARMA3 deficient mouse embryonic fibroblasts (MEFs) after exposure to
lysophosphatidic acid and endothelin-1, which are ligands for two distinct GPCRs.
Mechanistically, CARMA3 interacts with Nemo and regulate Nemo-associated
polyubiquitination, by which CARMA3 deficiency leads to the impaired kinase activity of
IKK complex(Grabiner, Blonska et al. 2007). Consistently, it has been found that Bcl10 and
MATL1 also play an essential role in some GPCR-induced NF-κB activation in different
cellular context (McAllister-Lucas, Ruland et al. 2007, Wang, You et al. 2007, Rehman and
Wang 2009, McAllister-Lucas, Jin et al. 2010). In summary, these studies suggest that CBM
complex is required for GPCR-induced NF-κB activation.
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Recently, a study has revealed the important role of CARMA3 in the epidermal growth
factor receptor (EGFR)-induced activation of NF-κB (Jiang, Grabiner et al. 2011). EGFR is a
transmembrane tyrosine kinase receptor and belongs to the HER family of receptor. EGFR
plays an essential role in regulating cell proliferation and differentiation, by which EGFR
contributes to a number of malignancies. EGFR activates many downstream signaling
cascades, including signaling pathway leading to activation of NF-κB signaling pathway,
through its receptor tyrosine kinases (RTK). Both CARMA3 and BCL10 deficiency impairs
EGF-induced activation of the IKK complex, resulting in a defect of IκBα phosphorylation
and NF-κB activation. Furthermore, CARM3 and BCL10 contribute to EGFR-associated
malignancy both in vivo and in vitro (Jiang, Grabiner et al. 2011). Several studies support the
clinical significance of CARMA3 in different types of cancer. For example, in non-smallcell lung cancer (NSCLC), the overexpression of CARMA3 correlates with cancer
progression, EGFR mutation and overexpression (Li, Qu et al. 2012). Besides, in colon
cancer, CARMA3 is overexpressed, which facilitates the disease progression by regulating
NF-κB mediated transcription of cyclin D1 (Miao, Zhao et al. 2012).
Although significant progresses have been made to understand the function of CARMA3
in NF-κB signaling pathway, the precise mechanism remains largely unknown. Future
investigations are needed to answer these questions: 1) how is CARMA3 activated in
different cellular context? 2) How is the CARMA3 linked for the receptors? 3) Which PKCs
is involved in regulating CARMA3 complex? 4) Does CARMA3 contribute to other
signaling pathways or diseases? These studies will provide us the insight into the molecular
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mechanism of CARMA3 in NF-κB signaling pathway, by which the researchers can develop
interference therapeutic targeting CARMA3 for cancer and other diseases.

1.5 Influenza and VSV

Influenza or flu is an infectious disease caused by viruses, which are capable of infecting
many animals including birds and mammals. Seasonal influenza virus in humans leads to
widespread epidemics and is a serious public health problem. For example, the 1918 flu
pandemic was the most lethal and famous outback. 1918 influenza pandemic lasted from
1918 to 1919. Although the exact number of people who died from the disease was unknown,
it was estimated that 50 to 100 million people died during the flu outbreak. The death of
millions people might be due to the high infection rate and extreme severity of the symptoms,
which may be caused by virus-induced cytokine storm(Patterson and Pyle 1991). Even in
modern society, the influenza pandemic endangers people lives. The threat of influenza virus
to public health urges researchers to better understand influenza virus and its-related host
immune response, which may facilitate developing the corresponding therapeutic
interference.
Influenza virus is RNA virus, which belongs to the family of Orthomyxoviridae. The
influenza virus is classified into three types, A, B and C. Among them, influenza A virus is
the most common one and usually causes the most serious problems in humans(Medina and
Garcia-Sastre 2011). Additionally, our research mainly focused on influenza A virus and its
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related host immune response. Therefore, in the following sections of this chapter, we will
mainly focus on influenza A virus.
Influenza A viruses are negative-sense, single-stranded RNA virus. Its segmented
genome consists of eight single-stranded negative-sense RNA molecules encoding 11 or 12
viral proteins. These viral proteins are nuclear export protein(NS2), the host antiviral
response antagonist non-structural protein 1(NS1), the matrix protein M1, the ion channel
M2, the receptor-binding protein haemagglutinin (HA), the sialic acid-destroying enzyme
neuraminidase(NA), nucleoprotein(NP), the components of the RNA-dependent RNA
polymerase complex(PB1, PB2 and PA) and N40(Wise, Foeglein et al. 2009, Medina and
Garcia-Sastre 2011).
These viral proteins play several roles for virus to complete its life cycle in host cells.
Specifically, HA proteins on the viral envelop interact with host cell receptors containing
terminal α-2,6-linked or α-2-3 linked sialic acid moieties, by which viruses are attached to
the host cells(Wagner, Matrosovich et al. 2002). Then, HA proteins are cleaved by cellular
protease to expose HA peptide, which is prerequisite for the fusion between viral envelop
and the cellular endosomal membrane(Steinhauer 1999). In this way, HA proteins determine
host tropism and systematic spread, affecting disease severity. When viruses enter cellular
endosome, the acidification of the vesicles opens the minor virus envelop protein M2, which
leads to acidification of the core of the virion(Pinto and Lamb 2006, Bouvier and Palese 2008,
Liu, Zhang et al. 2012). The process is required for uncoating and cytoplasmic release of the
ribonucleoprotein complex (RNP), where viral RNA genome is wrapped around NP. Then,
the complex is transported to the nucleus, when the negative-sense viral RNA((-) VRNA) is
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transcribed and replicated by the RNA-dependent RNA polymerase. During this process,
three different types of RNA molecules are generated, including the complementary positivesense RNA((+)cRNA), negative-sense small viral RNAs(svRNAs) and the viral mRNAs.
cRNA severs as a template to replicate more vRNA(Cros and Palese 2003). svRNAs play an
important role in regulating the change from transcription to replication(Perez, Varble et al.
2010). The viral mRNAs either are transferred to the cytoplasm for the translation of viral
protein or remain in nucleus. Some newly synthesized viral proteins are secreted onto the
cell surface through the Golgi apparatus, such as NA and HA and M2. Some viral proteins
are transferred into the nucleus to wrap progeny viral genome to form RNP complex for virus
packaging. Other viral proteins have multiple functions in host cells, including repressing the
IFN-mediated antiviral response, degrading cellular mRNA, and etc. In plasma membrane,
the influenza virus M1 protein facilitates the formation of virus particles. Then, budding
occurs and detaches from cells. The neuraminidase activity of NA is essential for budding, by
which the SA of the cellular and viral glycoproteins is destroyed. After virus completes its
life cycle in host cells, the host cells die(Medina and Garcia-Sastre 2011).
HA and NA not only play crucial roles in virus life cycle but also determine virus
serotypes. Until now, 18 known types of HA proteins and 11 known types of NA proteins
have been identified (Tong, Li et al. 2012). Base on the types of HA and NA protein on the
surface of the viruses, the influenza A virus are divided into different subtypes. For example,
H1N1 virus designates an influenza virus subtypes with a type 1 HA protein and a type 5 NA
proteins. Theoretically, there are possible 198 combinations of HA and NA proteins with
their corresponding virus subtype. In fact, virus strains circulating in birds are from 16 HA
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subtypes and nine NA subtypes, while virus strains circulating among humans are H1N1,
H1N2 and H3N2. H1N1 is responsible for “Spanish flu” and the 2009 swine flu outbreak,
H2N2 leads to the pandemic of “Asian flu” in the late 1950. H3N2 results in the Hong Kong
flu in the late 1960s (Air 1981, Nobusawa, Aoyama et al. 1991, Russell, Gamblin et al. 2004,
Fouchier, Munster et al. 2005).
Since HA and NA determines serotypes of influenza virus, any change in two proteins
affects host susceptibility and pathogenesis. Changes in HA and NA proteins occur through
two different ways. One is antigenic drift, which is characterized by the amino acid changes
in HA and NA proteins of new virus strains. The antigenic drift is caused by the virus' RNA
polymerase with no proofreading mechanism, which results in an error rate
between 1×10−3 and 8×10−3 substitutions per site per year during the replication of viral
genome replication. Therefore, most of newly synthesized viruses are mutants, which
partially overcome the protective immunity and are mainly responsible for seasonal influenza
pandemic. Another way is antigenic shifts, which is characterized by the dramatic change in
HA subtype. Antigenic shifts help viruses to quickly overcome the protective immunity and
to infect new host species, leading to the emergence of new pandemics(Medina and GarciaSastre 2011).
VSV is a negative strand RNA virus too, which belongs to the rhabdovirus family, and
has been widely used to study the host innate immune response against single strand RNA
virus. VSV genome is a single molecule of negative-sense RNA with 11,161 nucleotides
long, encoding five major viral proteins. These viral proteins are nucleoprotein, matrix
protein(M), phosphoprotein, large protein(L) and G protein(Lichty, Power et al. 2004).
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Those proteins play several roles in different stages of viral life cycle and facilitate virus
to complete its life cycle in host cells. Specifically, VSVG is required for viral entry by
mediating virus attachment to an LDLR family member present on the cell surface.
Following viral attachment, the VSV-LDLR complex undergoes quick endocytosis, where
the viral envelope is fused with endosomal membrane and releases viral genome to the
cytoplasm. In cytoplasm, the virus genome is either replicated with the facilitation of viral
protein VSV L protein and phosphoprotein or translated for new viral proteins(Finkelshtein,
Werman et al. 2013).The mature viral protein and new virus genome are packaged into a new
virus budding from the host cells.
Since VSVG has a broad host range, VSV is capable of infecting many distinct
mammalian and nonmammalian cell types. Therefore, VSV can infect many species
including cattle, horses, pigs, insects and humans. In some cases, it can cause flu-like
symptom in infected humans (Lichty, Power et al. 2004). Therefore, VSV is a good
experimental tool for investigating host innate immune responses against RNA virus
infection.

.
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CHAPTER 2: MATERIALS AND METHODS
2.1.

Antibodies, Plasmids, and Reagents

Antibodies against p-TBK1(Ser172)(#5483), p-IRF3(Ser396 )(#4947), TBK1(#3013),
RIG-I(#4743), IκBα(#4814) were purchased from Cell Signaling Technology. Antibodies
against IRF3 (FL-425), BCL10 (H-197), TRAF6 (H-274), ACTIN (#8432, clone C-2), HA
(sc-805), OctA-probe (D-8) (FLAG: sc-807), were from Santa Cruz Biotechnology. The
specific CARMA3 antibody was generated by immunizing rabbits with the small peptide
VRGRILQEQARLVWVEC, matching to the C terminus of human and mouse CARMA3.
Then, the antibody was purified by the same peptide-conjugated columns. The MAVS
antibody was a kind gift from Dr. Zhijian "James" Chen’s Lab. NF-κB or OCT-1bindingsite-specific probes were obtained from Promega. TRIzol reagent (15596-026),
Lipofectamine 2000 Transfection Reagent (11668-019), Superscript III First-Strand
Synthesis system (18080-051) were obtained from Invitrogen. Fast SYBR Green Master Mix
was purchased from Applied Biosystems (4385612). Mouse IFN Beta ELISA Kit was
obtained from PBL Assay Science (42400-2) , while Mouse IL-6 ELISA Ready-SET-Go KIT
was purchased from Affymetrix bioscience(88-7064-86). Poly (I:C) LMW(tlrl-picw-250),
5'ppp-dsRNA(tlrl-3prna-100) and 5ppp-dsRNA control(tlrl-3prna) were purchased from
InvivoGen. Influenza A/PR/8/34(H1N1) was purchased from Charles River. NF-κB
Inhibitors (213546-53-3), polybrene (sc-134220) was obtained from Santa Cruz.
Cycloheximide was purchased from Sigma (C7698). PCMV-Tag4-CARMA3 and its
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derivatives (CD-CC, ∆CD-CC, ∆SH3-GUK, ∆GUK) that encode Flag-tagged CARMA3 WT
or mutants have been described previously (Sun and Lin 2008). RIG-I, IKKε, MAVS and
TBK1 plasmids were obtained from Addgene. Myc-tagged BCL10 has been described
previously (Blonska, Pappu et al. 2007). shRNA against GFP, CARMA3 or BCL10 were
obtained from Sigma.

2.2.

Cell Cultures

WT, CARMA3 deficient, BCL10 deficient and MALT1 deficient mouse embryonic
fibroblasts (MEF) cells were isolated from mouse embryos from corresponding knockout
mice and prepared as previously described (Grabiner, Blonska et al. 2007). MEF cells,
human neuroblastoma SKNAS cells and human lung adenocarcinoma epithelial A549 cells
were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. MEF cells were grown in
8.5% CO2 at 37°C and passaged every three days. SKNAS and A549 cells were grown in 5%
CO2 at 37°C and passaged every two days.

2.3.

Electrophoretic Mobility Shift Assay (EMSA)

Nuclear extraction and EMSA were performed as described previously (Grabiner,
Blonska et al. 2007). Briefly, nuclear extracts were isolated from 1×106 cells stimulated for
appropriate times with different agents. Then, nuclear extracts (1–10 µg) were incubated with
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P-labeled NF-κB and OCT-1 probes at room temperature for 15 minutes. After incubation,
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the mixed samples were loaded into a native 10% acrylamide gel (1×Tris-borate-EDTA) and
run for 85 minutes at 220V. The gels were dried in a vacuum gel drying system and then
exposed to X-ray film.

2.4.

Western Blotting and Immunoprecipitation

Various types of cells were lysed in a lysis buffer containing 50 mM HEPES (pH 7.4),
150mM NaCl(or in the range of 50–250 mM NaCl), 1 mM EDTA, 1% NP-40, 1 mM
Na3VO4, 1mM PMSF, 1 mM NaF, 1mM DTT, and 1×protease inhibitor cocktail (Roche
Diagnostics). The cell lysates were subjected with immunoblotting by the indicated
antibodies or immunoprecipitated with various antibodies-conjugated beads. For
immunoprecipitation, the antibodies-conjugated beads were incubated with the cell lysate
overnight at 4˚. After incubation, the beads were washed with cold 1×PBS. Then, the
precipitates were eluted by 2×loading buffer and were subjected to SDS-PAGE and
immunoblot.

2.5.

Quantitative RT-PCR (qRT-PCR)

Total RNA isolation was isolated using TRIzol reagent (Invitrogen) according to the
manufacturer's instructions. Reverse transcription was performed by the SuperScriptIII FirstStrand Synthesis System with 1 µg of total RNA according to the manufacturer's instructions
with 50 µM oligo(dT) or random hexanucleotides. Then, qRT-PCRs were performed using
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the cDNA with gene-specific oligonucleotide primers (10 pM each). The primers used are
listed in Table 2.

2.6.

Lentivirus Infection for shRNA Knockdown

Lentivirus encoding control shRNA, CARMA3 shRNA and BCL10 shRNA was
generated as previously described (Jiang, Grabiner et al. 2011). Briefly, HEK 293 cells were
transfected with Lentivirus plasmids with packaging vectors encoding VSV-G and Dr.82 to
generate viruses. At 12 hours after transfection, the supernatant was replaced with the fresh
medium. The supernatant was collected from the HEK 293 cells at 48 hours after transfection
and centrifuged at 2000×g for 10 minutes to get rid of any cell debris. Then, the supernatant
was incubated with target cells for infection in presence of 8 µM polybrene overnight. One
day after virus infection, the infectious medium was replaced with media containing 1 µg/ml
puromycin for the selection. Four days after puromycin selection, the resultant pools were
used for experiments.

2.7.

Semidenaturing Detergent Agarose Gel Electrophoresis(SDD-AGE)

SDD-AGE was performed as previously described (Hou, Sun et al. 2011). In brief,
crude mitochondrial were isolated from cells stimulated for appropriate time with various
reagents. Then, the crude mitochondrial were resuspended in 1×sample buffer containing
0.5×TBE, 10% glycerol, 2% SDS, and 0.0025% bromophenol blue. The mixed samples
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were separated in a vertical 1.5% agarose gel in the running buffer (1×TBE and 0.1% SDS)
for 35 min with a constant voltage of 100 V on ice. After running, the proteins were
transferred to nitrocellulose membranes (Bio-Rad) for immunoblotting by indicated
antibodies.

2.8.

VSV and Influenza virus mouse model

Groups of six 4–6 weeks old WT and CARMA3 or BCL10 deficient mice were
intranasally inoculated with 20 µl of H1N1 influenza virus at pfu=600 in PBS under
isofluorane sedation. Mice survival and body weight were measured daily until 14 days postinfection (dpi). Moribund mice were considered as losing body weight >20% of their initial
or exhibiting severe disease. Moribund mice were humanely sacrificed.
Groups of 4–6 weeks old WT and CARMA3 or CARMA1 mice were intranasally
inoculated with 20 µl of VSV at pfu=1×107 in PBS under isofluorane sedation. Mice serum
was harvested at 24 hours after infection, while different tissues (lung, brain and spleen) were
harvested at 2 days after infection.

2.9.

Influenza TCID50 Assay

MDCK cells were cultured in high glucose DMEM containing 10% FBS and 1%
Pen-Strep in a T75 at 37oC. One day before TCID50 assay, 2×103 cells were seeded in 96 well
plates with 150µL of medium. In next day morning, influenza samples were thawed and
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homogenized on ice with 600µl medium, which was transferred into the 1st tube of the
dilution series and then serially dilute 184 µL across the tubes on ice. 100 µL of diluting
sample was incubated with cells at 37oC for 1 hour in the presence of 1ug/ml TPCK treated
trypsin. After incubation, the infectious medium was replaced with fresh 150uL DMEM with
1µg/ml TPCK treated trypsin. After 3 days of incubation, the medium was aspirated off and
replaced with 200 uL of a crystal violet working stock (40 mL 1% Crystal Violet, 80 mL
Methanol, 300 mL H2O). Cells were stained with crystal violet working stock for 1 hour and
rinsed with tap-water.

2.10.

Luciferase Reporter Assay

Luciferase assays were performed as described previously (44). In brief, HEK 293 cells
were seeded in triplicates in 12-well plates and transfected with 100 ng of NF-κB-responsive
luciferase and IFNβ promoter-dependent luciferase constructs encodes the firefly luciferase
and 10 ng of EF1α promoter-dependent Renilla luciferase reporter together(as a transfection
control) with 1.5 µg of expression vectors for different proteins or vector controls. At 16
hours after transfection, the cells were harvested and lysed to detect luciferase activities by
dual-luciferase kit (Promega).

2.11.

VSV plaque assay
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The medium containing virus was diluted with DMEM and prepared for VSV
plaque assay. The tissue samples were homogenized and the supernatant was used for VSV
plaque assay. The VSV plaque assay protocol was previously described. Briefly, at 1 hour
after infection, the infectious medium in cells was replaced with complete medium
containing 0.5% methylcellulose (Sigma-Aldrich) for 48 hrs. Then, BHK cells were fixed in
fixation solution and stained with crystal violet working solution. Virus titers were expressed
as PFU per milliliter, which counts the plaques in well. VSV plaque assay for each sample
was triplicated, and the averages of the virus titers were calculated.

2.12.

Isolation of crude mitochondria

Crude mitochondrial was isolated as described previously (Hou, Sun et al. 2011).
Briefly, cells simulated with appropriate reagents for indicated time were washed with icecold PBS twice and harvested by centrifuging at 600g for 3 minutes. Hypotonic buffer was
used to swell the cells for 2.5 minutes at 4°C. Hypotonic buffer contains 10mM KCl, 0.5mM
EGTA, 10mM Tris-Cl, pH7.5, 1.5mM MgCl2, 1mM PMSF, and 1x EDTA-free protease
cocktail. Then, the swollen cells were homogenized for 40 strokes in a tight-fitting Douncer
Homogenizer at 4°C. The supernatant was centrifuged at 600g for 5 minutes to remove the
insoluble parts. The resulting supernatant was centrifuged at higher speed to collect the
mitochondria. The crude mitochondria was resuspended in mitochondria resuspend buffer
(MRB) ,containing 0.5mM EGTA, 1mM PMSF, 20mM HEPES-KOH, pH7.4, 1x EDTA-free
protease cocktail, 0.8M sucrose and then, centrifuged at 7,000g for 10 minutes. The pellet
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was resuspended and centrifuged again. The resulting pellet was resuspended in MRB buffer
with 2% CHAPs and was incubated in ice bath for 15 min. The mitochondria lysates were
mixed with 2X loading dye (1 × TBE, 10% glycerol, 4% SDS, and 0.005% bromophenol
blue) containing no reduction reagents.

2.13.

Bone marrow-derived macrophage (BMDM) preparation.

Primary cultures of BMDMs from WT or CARMA1 deficient mice were isolated from
tibias and femurs of WT or CARMA1−/− mice as previously described (Bi, Gojestani et al.
2010, Gorjestani, Yu et al. 2011). In brief, after isolation, the mix cells were incubated in
hypotonic solution for 10 minutes to get rid of erythrocytes. The resulting cells were
cultured in DMEM containing 20% FBS, 55 µM β-mercaptoethanol, 100 µg/ml streptomycin,
100 U/ml penicillin, and 30% conditioned media from L929 cells expressing macrophage
CSF (M-CSF) for 7 days. At 3 days after isolation, the medium was replaced with the fresh
one to remove non-adherent cells. After 1 wk of cultures, cells was stained with
combinations of fluorescence-conjugated monoclonal antibodies (CD11b+ and F4/80+) and
analyzed by flow cytometry to assess the cellular purity. Cell population contained 86–95%
CD11b+ F4/80+cells.

2.14.

Splenocyte Isolation and Staining
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Splenocytes were isolated from the spleen of different types of mice. Briefly, the spleens were
transferred into the cell strainer in the Petri dish and washed with 1ml pre-cold PBS. The spleen was
mashed by the black rubber end of 2ml syringe to relase the splenocytes into the Pertri dish. The
homogenized cell suspension was transferred to a new tubes and was collected by centrifuge at 400×g
for 10 minutes. The resulting cells was washed with 1ml pre-cold PBS once and were incubated with
hypotonic solution for 15 minutes to get rid of erythrocytes. The resulting cells were washed with
PBS again and were ready to stain with the fluorescence-conjugated monoclonal antibodies(CD11c+).

2.15.

Stable isotope labeling by amino acids(SILAC) experiments

All SILAC experiment-related reagents were bought from Pierce (Thermo Scientific). SILACDMEM medium deficient in lysine and arginine were supplemented with L-lysine, L-arginine, 10%

dialyzed fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. HEK 293T
cells expressing empty vector were cultured in the “light” medium supplemented with Lys0 (12C6)
and Arg0 (12C6), while HEK293T cells transiently expressing CARMA3-FLAG were culture in the
‘heavy’ culture with Lys8 (13C6) and Arg10 (13C6). 48 Hours after transfection, cells were lysed

in a lysis buffer containing 50 mM Tris (pH 7.4), 150mM NaCl, 1 mM EDTA, 2% DDM,
and 1×protease inhibitor cocktail (Roche Diagnostics). The same amounts of cell lysates of
more than 1 mg were immunoprecipitated with FLAG antibodies-conjugated beads. The
proteins-bead were washed 3 times with cold lysis buffer. The proteins were eluted with
FLAG peptides(100µg/ml) and merged together before subjecting to SDS-PAGE and silver
staining. Then, gel slices from SDS-PAGE lanes were excised and digested with trypsin. Peptides
generated by protease digestion were fractionated on a analytical column (75 µm ID, 100 mm in
length) packed with C18 resin by Dionex Ultimate 3000 nanoLC system (Thermo Scientific). The
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column was coupled in-line to a Q Exactive mass spectrometer (Thermo Scientific) equipped with a
nano-electrospray ion source. MS/MS spectra (resolution: 17,500 at m/z = 200) were acquired in a
data-dependent mode, whereby the top 15 most abundant parent ions were subjected to further
fragmentation by higher energy collision induced dissociation (CID). MS raw data was searched
against Swissprot database(Homo Sapiens) using mascot searching engine and was quantified with
mascot distiller. The MS tolerance was set to 15 ppm, and the MS/MS tolerance was set to 20 mmu.
To define a reliable peptide, the score should exceed the identity threshold given by Mascot,
meanwhile, the false discovery rate (FDR) at protein levels was set to 0.01. For the quantification of
the identified proteins, Mascot Distiller software (Version 2.5.1.0) was used to calculate the ratios
between the heavy- and light-labeled IP products (H/L) at both peptides and proteins level. For the
quality control, the threshold of standard error for each XIC pair was set to 0.1, and the threshold of
correlation coefficient between the predicted and observed precursor isotope distributions was set to
0.7. Only peptides exceeding the homology threshold were used for the quantification.
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CHAPTER 3: RESULTS

3.1.CARMA3 deficiency caused mouse to be more resistant to influenza infection.

Using collaborative cross (CC) mouse model of influenza infection, the researchers found
that genetic variations in CARMA3 regulated differential response phenotypes to influenza
infection(Ferris, Aylor et al. 2013). However, the role of CARMA3 in influenza infection
remains largely unknown. To confirm the important role of CARMA3 in influenza infection,
we infected WT and CARMA3 deficient mice with H1N1 influenza virus at pfu=600. Then,
we measured the change of mice bodyweight daily until 14 days after virus infection. We
found that WT mice lose more body weight than CARMA3 deficient mice until the end of
experiments (Fig.5A). Next, we decided to detect the virus replication in mice. The WT,
CARMA3+/- and CARMA3 deficient mice were intranasally injected with influenza at
pfu=500. Two days later, we harvested the lungs from mice. The influenza virus titer in lungs
was measured by tissue culture infectious dose (TCID50) assays. We found that there was less
virus titer in lungs from CARMA3 deficient mice than that from WT or CARMA3 Het mice.
It might explain why WT mice losed more body weight than CARMA3 deficient mice during
the experiments (Fig.5B). These data suggested that CARAM3 deficiency caused mice more
resistant to influenza infection.
After influenza virus infection, its RNA genome is recognized by PRRs to trigger the
production of proinflmmatory cytokines and type I IFNs(Medina and Garcia-Sastre 2011).
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Among them, IL6 and IFNβ are the important cytokines. The transcription of IL6 is
controlled by transcription factor NF-κB, while the expression of IFNβ is mainly mediated
by the transcriptional factor IRF3 (Sato, Suemori et al. 2000, Xiao, Hodge et al. 2004, Honda,
Yanai et al. 2005). The lung and serum were harvested from the infected mice 3 days after
infection. The level of serum IL6 and lung IFNβ were measured by ELISA and qRT-PCR,
respectively. We found that CARMA3 deficient mice had more lung IFNβ but less the serum
IL6 after virus infection (Fig.6).

3.2.CARMA3 deficiency caused mice to be resistant to VSV infection.

VSV also is a negative single-stranded RNA virus. To check whether CARMA3
contributes to the variable host responses to RNA virus infection, we challenged WT and
CARMA3 deficient mice intranasally with VSV-GFP at 1×107 pfu. We harvested serum and
tissues at 24 hrs and 48 hrs after infection, respectively. The virus titer in different tissues
was measured by viral plaque assay. The level of serum IL6 and IFNβ were measured by
ELISA. There was less virus titer in the CARMA3 deficient mice than that in WT mice in
different tissues including spleens, olfactory bulbs (OB) and lungs, which suggested the
negative role of CARMA3 in VSV infection in vivo(Fig.7). Next, we decided to check the
level of serum IL6 and IFNβ. Surprisingly, the level of serum IL6 and IFNβ was comparable
between WT and CARMA3 deficient mice. Since the CARMA3 is only expressed in nonhematopoietic tissues, we decided to further check the local IFNβ and IL6 production by
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qPCR in OB(Jiang and Lin 2012). We found that there was more IFNβ in the OBs from
CARAM3 deficiency mice than those from WT mice (Fig.8).
To check the negative role of CARMA3 in VSV infection in vitro, we infected primary
WT and CARMA3 deficient MEF cells with VSV at MOI=10. One hour after infection, the
infectious medium was replaced with fresh medium to get rid of uninfected virus. At 24 hrs
after infection, we measured the virus titer in supernatant using viral plaque assay. We found
that there was less viral titer in supernatant from CARAM3 deficient cells than that from WT
cells. Next, we obtained lentivirus constructions encoding control shRNA and CARMA3
shRNA, which significantly inhibited CARMA3 mRNA transcription. We infected different
cell lines, such as A431, Hela with lentivirus construction encoding control shRNA or
CARMA3 shRNA. Then, we examined the virus titer from supernatant using the protocol as
described previously. We found that there was less viruses in the supernatant from CARMA3
knockdown cells than that from control knockdown cells (Fig.11). It suggested that
CARMA3 deficiency or knockdown caused cells more resistant to VSV infection.

3.3.

The activation of NF-κB signaling pathway was reduced in CARMA3
deficient cells after VSV infection.

It was found that the CARMA3 was required for NF-κB activation induced by some
GPCRs and receptor tyrosine kinases in non-hematopoietic tissues (Grabiner, Blonska et al.
2007, Klemm, Zimmermann et al. 2007, McAllister-Lucas, Ruland et al. 2007, Mahanivong,
Chen et al. 2008). To determine whether CARMA3 was involved in VSV-induced NF-κB
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activation, we first infected WT and CARMA3 deficient MEF cells with VSV at MOI=3.
We detected the activation of NF-κB signaling pathway by EMSA at different time points.
We found the activation of VSV-induced NF-κB was decreased in CARMA3 deficient MEF
cells, compared to WT cells. It suggested that CARMA3 played a positive role in VSVinduced NF-κB activation (Fig.9A). To further confirm the positive role of CARMR3 in
VSV-induced NF-κB activation, we decided to check the production of IL6 in WT and
CARAM3 deficient MEF cells upon VSV infection, since the transcription of IL6 is
controlled by NF-κB (Xiao, Hodge et al. 2004). The level of IL6 was measured at 6,12 hours
after virus infection by both qPCR and ELISA. We found there was less production of IL6 in
CARAM3 deficient MEF cells than that in WT cells (Fig.9 B&C).

3.4.

CARMA3 deficient cells increased IFN-β production after VSV infection.

IFNβ secreted by cells plays an important role in inhibiting virus infection(Schneider,
Chevillotte et al. 2014). Since previous data showed that tissues in CARMA3 deficient mice
produced more IFNβ after virus infection, we decided to detect the production of IFNβ in
cells after virus infection. WT and CARMA3 deficient MEF cells were infected with VSV at
MOI=3. At the different time points, the production of IFNβ was measured by qPCR or
ELISA. We found that CARMA3 deficient cells produced more IFNβ after virus infection,
compared to WT cells (Fig.10 A&B).
It has been established that the production of IFNβ was controlled by TBK1-IRF3
signaling pathway. Since there was increased production of IFNβ in CARMA3 deficient cells
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after VSV infection, we decided to check the activation of TBK1-IRF3 signaling pathway in
different cell types after virus infection. The WT and CARMA3 deficient MEF cells were
infected with VSV at MOI=3. The activation of TBK1-IRF3 signaling pathway was
measured by immunoblotting using specific p-TBK1 (Ser 172) and p-IRF3 (Ser 396)
antibodies. We found that the phosphorylation of TBK1 and IRF3 were increased in
CARMA3 deficient MEF cells. It suggested that the activation of TBK1-IRF3 signaling
cascade was enhanced in CARMA3 deficient cell (Fig.10C). These data suggested that
CARMA3 played a negative role in the virus-induced activation of TBK1-IRF3 signaling
pathway.

3.5 CARMA3-deficient MEF cells had decreased activation of NF-κB signaling
pathway and thereby, produced less IL6 after poly(I:C) transfection.

Both VSV and influenza are ssRNA viruses. When they infect cells, their RNA genome
are recognized by both TLR3 and RIG-I(Jacobs and Coyne 2013). To specify the role of
CARMA3 in RIG-I/MAVS signaling pathway, we decided to transfect cells with specific
ligands of the RIG-I/MAVS signaling pathway such as poly (I:C) and 5’ppp-dsRNA. Poly
(I:C) is a synthetic analog of dsRNA, a PAMP associated with RNA virus infection. Naked
poly(I:C) is recognized by TLR3 on the cell surface(Lester and Li 2014). However, when
poly (I:C) is transfected into cells, it can be specifically recognized by cytoplasmic RIG-I and
MDA5 receptors in a cell-dependent manner(Kato, Sato et al. 2005, Gitlin, Barchet et al.
2006). WT and CARAM3 deficient MEF cells were transfected with 1 ug/ml poly(I:C) by
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lipotofactamine 2000. We measured the activation of NF-κB by EMSA and the production of
IL6 by qPCR and ELISA. Both the activation of NF-κB and the production of IL6 were
decreased in CARMA3 deficient cells after poly(I:C) transfection at the different time points.
It suggested the positive role of CARMA3 in RIG-I/MAVS-mediated NF-κB signaling
pathway (Fig.12).

3.6 CARMA3-deficient MEF cells had increased activation of IRF3 signaling
pathway and thereby, produced more IFNβ after poly (I:C) transfection.

WT and CARMA3 deficient MEF cells were transfected with poly (I:C) with
lipotofactamine 2000. The activation of TBK1-IRF3 signaling pathway was measured by
immunoblotting using the specific p-IRF3 (Ser396) antibodies. We found that IRF3 signaling
pathway was activated in WT cells after poly (I:C) transfection, but the activation was
increased in CARMA3 deficient MEF cells (Fig.13D). Consistently, the production of type I
IFNs in CARAM3 deficient MEF was more than that in WT cells after poly(I:C) transfection.
It suggested that CARMA3 negatively regulated RIG-I-mediated TBK1-IRF3 signaling
pathway (Fig.13 A, B and C).

3.7 CARMA3-deficient MEF cells produced less IL6 but more IFNβ after dsRNA
transfection.
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To verify the role of CARMA3 in RIG-I/MAVS signaling pathway, we decided to use
another specific ligand: 5' ppp-dsRNA. 5' ppp-dsRNA is a synthetic ligand specific for RIG-I.
The WT and CARMA3 deficient MEF cells were transfected with 1ug/ml 5' ppp-dsRNA by
lipofectamine 2000. We measured the production of type I IFNs and IL6 by qPCR and
ELISA. We found that CARMA3 deficiency impaired 5' ppp-dsRNA-induced IL6
production (Fig.14). On the other hand, CARMA3-deficient cells produced more type I IFNs
after ligand transfection (Fig.15). Together, these data suggested the dual role of CARMA3
in RIG-I/MAVS-mediated activation of NF-κB and IRF3 signaling pathways. Specifically,
CARMA3 played a positive role in RIG-I/MAVS-mediated NF-κB signaling pathway, but a
negative role in TBK1-IRF3 signaling pathway.

3.8

BCL10 deficient cells had decreased activation of NF-κB signaling pathway, but

increased activation of TBK1-IRF3 signaling pathway after virus infection and poly
(I:C) transfection.

Previous studies demonstrated that CARMA3 interacted with BCL10 and MALT1 to
form CBM complex, which regulated the activities of IKK complex through mediating
NEMO-associating polyubiquitination (Grabiner, Blonska et al. 2007). Therefore, we
hypothesized that BCL10 is involved in RIG-I-mediated NF-κB activation. To test the
hypothesis, we treated WT and BCL10 deficient MEF cells with VSV infection or poly (I:C)
transfection. The production of IL6 was measured by both qPCR and ELISA. We found that
BCL10 deficiency impaired both virus infection and poly (I:C) transfection-induced IL6
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production (Fig.18). It suggested that BCL10 played a positive role in RIG-I /MAVSmediated NF-κB signaling pathway, which was similar to CARMA3.
Next, we decided to test the role of BCL10 in RIG/MAVS-mediated TBK1-IRF3
signaling pathway. We treated WT and BCL10 deficient MEF cells with VSV infection and
poly (I:C) transfection. We detected the activation of TBK1-IRF3 signaling pathway and the
production of type I IFNs, using the methods as described previously.BCL10 deficiency
caused cells to produce more type I IFNs after both VSV infection and poly(I:C) transfection.
Consistently, the activation of TBK1-IRF3 signaling pathways was enhanced in BCL10deficienct cells after treatments. It suggested that BCL10 played a negative role in the
activation of RIG-I/MAVS-mediated TBK1-IRF3 signaling pathway, which is similar to
CARAM3 (Fig.17).
To further demonstrate the role of CARMA3 and BCL10 in RIG-I/MAVS signaling
pathways, we obtained three different lentivirus constructions encoding control shRNA,
CARAM3 shRNA and BCL10 shRNA. We infected A549 cells with different lentiviruses to
significantly suppress the expression of CARMA3 or BCL10. We compared the activation
of NF-κB and IRF3 signaling pathway among cells stably expressing control shRNA,
CARMA3 shRNA and BCL10 shRNA upon VSV infection or poly (I:C) transfection. Cells
with control knockdown produced IL6 and IFNβ after VSV infection or poly (I:C)
transfection, whereas cells with CARMA3 or BCL10 knockdown produced more IFNβ, but
less IL6 after treatments(Fig.20). Consistently, the activation of TBK1-IRF3 signaling
pathway was enhanced in cells with CARMA3 or BCL10 shRNA, compared to cells with
control knockdown (Fig.19).
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3.9 BCL10 deficiency caused mice to be more resistant to VSV infection.

Our previous data suggested that CARMA3 deficiency led to mice more resistant to VSV
infection. Since BCL10 always functions together with CARAM3 to form a complex, we
hypothesized that BCL10 deficiency also causes mice to be more resistant to VSV infection
(Grabiner, Blonska et al. 2007). Groups of 6-8 weeks WT and BCL10 deficient mice were
intranasally injected with VSV-GFP at pfu=1×107. The virus titer in different tissues was
measured by viral plaque assay. WT mice had more virus titer in different tissues than
BCL10 deficient mice did. It suggested that BCL10 deficiency caused mice to be more
resistant to VSV infection, which is similar to CARAM3 deficient mice (Fig.21).
Together, our data suggested that BCL10 functioned as a partner with CARMA3 to
regulate RIG-I/MAVS-mediated signaling pathways.

3.10

MALT1 deficiency did not impair VSV infection or poly (I:C)
transfection-induced NF-κB activation.

Previous study showed that MALT1 was an important component of CBM complex,
which regulated NF-κB signaling pathway through IKK complex (Grabiner, Blonska et al.
2007). Therefore, we hypothesized that MALT1 contributes to VSV-induced NF-κB
activation. We treated WT and MALT1 deficient MFE cells with VSV infection. We found
that the activation of NF-κB and the production of IL6 were comparable between two cells
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types after virus infection (Fig.22C& Fig.23). It suggested that MALT1 deficiency did not
impair RIG-I/MAVS-mediated NF-κB activation.

3.11

MALT1 deficiency did not enhanced VSV or poly (I:C) transfectioninduced IRF3 activation.

Our previous data showed that both CARMA3 and BCL10 play a negative role in VSV
infection and poly (I:C) transfection-induced IRF3 activation. Additionally, MALT1 always
forms a complex with CARMA3 and BCL10 in context of NF-κB signaling pathway.
Therefore, we hypothesized that MALT1 plays a negative role in RIG-I/MAVS-mediated
IRF3 activation. To test the hypothesis, we infected the WT and MATL1 deficient MEF cells
with VSV. We measured the activation of TBK1-IRF3 signaling pathway and the production
of type I IFNs according to protocols previously described. We found the activation of IRF3
signaling pathway and the production of type I IFNs were comparable between WT and
MALT1 deficient MEF cells(Fig.22 A and B& Fig. 24). It suggested that MALT1 did not
play a role in RIG-I/MAVS-mediated IRF3 activation.

3.12

The inhibition of NF-κB signaling pathway did not enhance the activation
of IRF3.

Both NF-κB and IRF3 are transcription factors. When they are active, they enhance
expression of genes in response to different stimulus(Oeckinghaus and Ghosh 2009).
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Additionally, based on our data, we found that NF-κB signaling pathway acted prior to
TBK1-IRF3 signaling pathway. Therefore, we hypothesized that NF-κB target genes inhibit
the activation of IRF3. To test the hypothesis, we pretreated the primary MEF with NF-κB
inhibitors and then infected the cells with VSV at MOI=3. The NF-κB inhibitor is a small
peptide, which specially targets the nuclear translocation signals in p50 and thereby, blocks
the nuclear translocation of the active NF-κB dimmers. The activation of NF-κB signaling
pathway was measured by EMSA, while the activation of IRF3 was measured by
immunoblotting using specific p-IRF3 antibody. NF-κB signaling pathway was activated by
VSV infection at different time points, whereas the activation was partially blocked by the
treatment of NF-κB inhibitor. It suggested that the NF-κB inhibitor worked well in the
experiments. On the other hand, the IRF3 was phosphorylated at different time points after
VSV infection. However, the IRF3 phosphorylation was not enhanced with the treatment of
NF-κB inhibitor during VSV infection. It suggested that NF-κB target genes did not inhibit
IRF3 activation (Fig.25). In other words, crosstalk between NF-κB and IRF3 signaling
pathway was not critical for the increased activation of IRF3 signaling pathway in CARMA3
deficient cells.

3.13

The inhibition of new protein synthesis did not rescue the enhanced

activation of TBK1-IRF3 signaling pathway in CARAM3 deficient cells

To further confirm it, we decided to pretreat primary MEF cells with 10 µg/ml
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cycloheximide (CHX) to block new protein synthesis. Then, cells were transfected with
1µg/ml poly (I:C) by lipofectamine 2000. At the different time points, the activation of IRF3
was measured by immunoblotting using specific p-IRF3 antibody. Compared to WT MEF
cells, the phosphorylation of IRF3 was increased in CARMA3 deficient MEF cells. The
enhancement cannot be blocked by CHX treatment. It suggested that CARMA3 and BCL10
directly regulated RIG-I/MAVS-mediated signaling pathways, not through the secondary
effect (Fig.26).

3.14

In RIG-I/MAVS signaling pathway, CARAM3 worked together with
MAVS.

Our previous data suggested that CARMA3 and BCL10 were directly involved in RIGI/MAVS signaling pathways. Next, we decided to investigate how CAMRA3 and BCL10
regulated IRF3 or NF-κB signaling network. To do that, we infected HEK 293 cells with
lentivirus encoding control shRNA, CARMA3 shRNA or Bcl10 shRNA. Then, we
overexpressed MAVS-FLAG in those cells together with NF-κB-responsive luciferase
construct or IFNβ luciferase reporter plasmids. The overexpression of MAVS could activate
both NF-κB and IRF3 signaling pathways in cells with control knockdown. There is
hyperactivation of IRF3 and hypoactivation of NF-κB in cells with CARMA3 or BCL10
knockdown. It suggested that CARMA3 and Bcl10 worked together with MAVS (Fig.27A).
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3.15

In MAVS/RIG-I signaling pathway, CARAM3 worked upstream of
TBK1 and IKKε

Next, we overexpressed TBK1-FLAG or IKKε-FLAG in HEK 293 cells stably
expressing control shRNA, CARMA3 shRNA or BCL10 shRNA, together with NF-κBresponsive luciferase constructs or IFNβ luciferase reporter plasmids. Overexpression of
TBK1-Flag induced the activation of both NF-κB and IRF3 signaling pathway in cells with
control knockdown, while the activation of these two signaling pathways was comparable in
cells with CARMA3 and BCL10 knockdown. When it came to IKKε overexpression, we
found the similar results. It suggested that CARMA3 worked upstream of TBK1 and IKKε in
MAVS/RIG-I signaling pathway (Fig.27 B, C&D).
Together, our data suggested that CAMRA3 worked downstream of MAVS, but
upstream of TBK1 and IKKε.

3.16

CARMA3 interacted with MAVS.

Similar to CARMA3, MAVS and RIG-I proteins contain CARD domain. It was
established that CARD domain was important for the interaction between CARD-domain
containing proteins(Blonska and Lin 2011). Additionally, our previous data showed that
CARMA3 worked downstream of MAVS. Therefore, we hypothesized that CARMA3
interacts with MAVS. To test the hypothesis, we decided to firstly detect the interaction
between CARMA3 and MAVS, when they are overexpressed in HEK 293 cells. We
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overexpressed CARMA3-HA with MAVS-FLAG or RIG-I-FLAG in HEK 293 cells. At 24
hours after transfection, we immunoprecipitated(IP) MAVS or RIG-I using anti-Flag
antibody conjugated beads. The immunoprecipitated complex and cell lysates were subject to
immunoblotting using indicated antibodies. We found that both CARMA3 and BCL10
interacted with MAVS, while BCL10 not CARMA3 was associated with RIG-I (Fig.28A).
To further confirm MAVS’s interaction with CARMA3, we decided to check the
endogenous interaction between CARMA3 and MAVS. We infected immortalized CARMA3
deficient MEF with lentivirus constructions encoding CARMA3-HA. Then, we infected cells
stably expressing CARMA3-HA with VSV at MOI=3. At different time points, we
immunoprecipitated CARMA3-HA using specific anti-HA antibody-conjugated beads or
control anti IgG-conjugated beads. The immunoprecipitated complex and cell lysates were
subject to immunoblotting using indicated antibodies. We found that CARMA3 inducibly
interacts with MAVS and BCL10 at 3 and 4 hours after virus infection (Fig.29A).
Besides, we found that CARMA3 was cleaved after virus infection. The immortalized
CARMA3 deficient cells stably expressing CARMA3-HA were infected with VSV at
MOI=3. We detected two bands at 3 hours after virus infection using anti-HA antibody. The
upper band was decreased, while the lower band was increased during virus infection. To
confirm the cleavage of CARMA3, we used specific anti-CARMA3 antibody, which raised
against the small peptides from both N-terminal and C-terminal of protein. We detected one
lower cleaved band. It suggested that CARMA3 was cleaved in the middle of protein
(Fig.29A).
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3.17

BCL10 interacted with MAVS and RIG-I.

Next, we decided to check the interaction between BCL10 and MAVS. We firstly
overexpressed BCL10-MYC and MAVS-FLAG or RIG-I-FLAG in HEK 293 cells and then
immuniprecipitated MAVS or RIG-I using anti-FLAG antibody conjugated beads. The
immunoprecipitated complex and cell lysates were subject to immunoblotting with the
indicated antibodies. We found that Bcl10 interacted with both MAVS and RIG-I, when they
were overexpressed (Fig.28B).
To further confirm the interaction between MAVS and BCL10, we decided to detect the
endogenous interaction between two proteins. The HEK 293 cells were transfected with
1µg/ml poly (I:C) by lipofectamine 2000. At the different time points, we
immunoprecipitated BCL10 and detected its interaction with MAVS. We found that BCL10
inducibly interacted with MAVS at 1 hour after poly (I:C) transfection. We cannot see the
interaction between BCL10 and MAVS at 2 and 3 hours after poly (I:C)
transfection(Fig.29B).

3.18

CARMA3 and BCL10 competed with RIG-I in binding with MAVS

It was found that RIG-I interacted with MAVS and triggered MAVS to form prionlike structure after virus infection (Hou, Sun et al. 2011). Our previous data showed that
CARMA3 and BCL10 interacted with MAVS. Therefore, we hypothesized that CARMA3 or
BCL10 competes with RIG-I in binding with MAVS. To test the hypothesis, we
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overexpressed MAVS-His and RIG-I-FLAG in presence of CARMA3-HA or BCL10-Myc in
HEK 293 cells. At 24 hours after infection, we immunoprecipitated MAVS using Ni-NTA
beads and detected its interaction with RIG-I, CARMA3 and BCL10 by immunoblotting. We
found that RIG-I interacted with MAVS in the absence of CARMA3 or BCL10. After the
overexpression of CARAM3 or BCL10, the interaction between MAVS and RIG-I was
blocked in a dose-dependent manner. In contrast, MAVS was associated with CARMA3 or
BCL10 even in the presence of RIG-I. Together, our data suggested that CARMA3 and
BCL10 competed with RIG-I in binding with MAVS (Fig.30).

3.19

CARMA3 interacted with CASPASE-3, CASPASE-8 and CASPASE -9.

There is a CARD domain at the N-terminal of CARAM3. CARD domain originates from
proteins involved in regulation of CASPASE proteins’ activation and recruitment(Jiang and
Lin 2012). CARMA3 was cleaved after virus infection. The cleavage sites might be located
in the middle of CARMA3. By sequence analyses, we identified a potential CASPASE 8
cutting site in the middle of protein. Therefore, we hypothesized that CARMA3 interacts
with CASPASE proteins after virus infection. To test the hypothesis, we infected A431 cells
with VSV at MOI=3. At the different time points after infection, we immunoprecipitated
CASPASE3, 8 and 9 using their specific antibodies-conjugated beads. CARMA3
constitutively interacted with CASPASE 3, 8 and 9. They interacted with each other with the
highest affinity at 4 hours after virus infection. At 8 hours after infection, we can only detect
the weak interaction between CARMA3 and CASPASE 3, while CASPASE 8 and 9 were
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dissociated from CARMA3 (Fig.38). The interaction between CARMA3 and CASPASE
proteins raised the possibility that CARMA3 was cleaved by CASPASE proteins. More
studies are needed to test the hypothesis.

3.20

The aggregation of MAVS was required for NF-κB and IRF3 activation

Previous studies showed that MAVS was aggregated to form a prion-like structure after
SeV infection. The prion-like structure of MAVS was important for MAVS to recruit many
different E3 ligases, such as TRAF6, TRAF2/5, linear ubiquitin assembly complex (Lubac)
complex, which work together to activate NF-κB and IRF3 (Hou, Sun et al. 2011). To
confirm it, we obtained two plasmids encoding MAVS WT or MAVS E26A and
overexpressed them with NF-κB-luc and IFN-luc in HEK 293 cells. It was found that MAVS
WT but not MAVS E26A formed prion-like structure, when they were overexpressed (Hou,
Sun et al. 2011). MAVS WT induced the activation of both signaling pathways, while the
mutant cannot. Next, we detected the level of these two proteins by immunoblotting. We
found that the level of these two proteins were comparable. Our data suggested that the
aggregation of MAVS was required for both NF-κB and IRF3 activation (Fig.31).

3.21

CARMA3 and BCL10 overexpression inhibited MAVS to form prion-like
structure.
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Our previous data showed that CARMA3 and BCL10 interacted with MAVS and
regulated MAVS function. Additionally, MAVS aggregation was essential for both NF-κB
and IRF3 activation. Therefore, we hypothesized that CARMA3 or BCL10 overexpression
inhibits MAVS aggregation. To test the hypothesis, we overexpressed different doses of
CARMA3-FLAG together with RIG-I-FLAG in HEK 293 cells. Then, we isolated
mitochondrial from transfected cells and analyzed MAVS aggregation by SDD-AGE assay.
We found that overexpression of RIG-FLAG led to MAVS aggregation, while the MAVS
aggregation was inhibited with increasing amount of CAMRA3 in mitochondrial (Fig.32).
Next, we decided to check the role of BCL10 in regulating MAVS aggregation. We
overexpressed different doses of BCL10 together with RIG-I-FLAG in HEK 293 cells. Then,
we decided to detect the MAVS aggregation using the methods as described before. We
found that BCL10 overexpression inhibited MAVS aggregation in a dose-dependent manner
(Fig.32).
Together, our data suggested that CAMRA3 and BCL10 overexpression inhibited MAVS
from aggregated form.

3.22

After virus infection, MAVS aggregation more easily occurred in cells
with CARMA3 deficiency.

To further confirm the negative role of CARMA3 in MAVS aggregation, we infected WT
and CARAM3 deficient MEF cells with VSV at MOI=3. At the different time points, we
measured the MAVS aggregation using the method as described previously. One hour after
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virus infection, MAVS did not undergo aggregation in WT cells, but MAVS aggregation
occurred in CARMA3 deficient cells. This trend became more obvious at 6 hours after virus
infection. Next, we checked the level of MAVS in WT and CARMA3 deficient MEF cells in
mitochondrial. We found that the level of MAVS was comparable between two cell types.
Therefore, our data suggested the negative role of CARMA3 in MAVS aggregation (Fig.33).

3.23

Schematic model of CARMA3 and BCL10-mediating MAVS aggregation
and MAVS-mediating signaling pathway.

Based on our previous data, we propose a model to describe how CARMA3 and BCL10
regulate MAVS aggregation in RIG-I/MAVS signaling pathways. In resting cells with no
virus infection, MAVS was kept as an individual form. After virus infection, RIG-I interacted
with MAVS and triggered the MAVS to form a prion-like structure. During the process,
CAMRA3 and BCL10 complex interacted with MAVS and was involved in the activation of
NF-κB signaling pathway. In the meantime, the CARMA3 and BCL10 complex inhibited
MAVS from more aggregated form. In CARMA3 deficient cells, virus infection triggered the
quick and easy MAVS aggregation. Therefore, in CARMA3 deficient cells, there was more
activation of TBK1-IRF3 signaling pathway. Since CARAM3 and BCL10 are involved in
NF-κB through unknown mechanism, there was partially defective of virus-induced NF-κB
activation (Fig.34).
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3.24

Compared to WT mice, CARMA1-deficient mice had less serum IFNβ
and IL6 levels after VSV-GFP infection

CARMA1 is another CARMA family member. Different from CARMA3, the CARMA1
is only expressed in the hematopoietic tissues. However, CARMA1 shared a high degree of
sequence and structural homology with CARMA3(Jiang and Lin 2012). Furthermore,
CARMA3 had an ability to rescue TCR-induced NF-κB activation in CARMA1-deficient T
cells, which suggested that CARMA3 and CARMA1 regulate the same signaling pathway in
a similar manner but in different tissues (Matsumoto, Wang et al. 2005). Therefore, we
hypothesized that CARMA1 contributes to the variable host responses to VSV infection,
similar to CARMA3. To test it, we challenged WT and CARMA3 deficient mice intranasally
with VSV-GFP infection. We checked cytokine production in serum and virus titer in brain.
We found that virus titer in CARMA1 deficient mice exhibits modestly decreased virus titer,
compared to WT mice. (Fig.35A). However, we surprisingly found that the serum IL6 and
IFNβ was significantly decreased in CARMA1 deficient mice at 24 and 48 hours after
infection, but the level of serum IFNε is comparable between two types of mice (Fig.35B). It
suggested that CARMA1 specifically regulated VSV-induced the production of IL6 and
IFNβ.

3.25

CARMA1 contributed to VSV-induced the production of IFNβ in
splenocyte and CD11c+ cells.
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Our previous data showed that the serum IL6 and IFNβ was decreased in CARMA1
deficient mice at 24 or 48 hours after VSV infection. It suggested that CARMA1 mainly
contributed to the innate immunity against VSV infection. Additionally, multiple dendritic
cell types served as major IFNs producing cells in vivo in response to RNA virus
infection(Colonna, Krug et al. 2002, Diebold, Montoya et al. 2003). Therefore, we
hypothesized that CARMA1 contributes to VSV-induced IL6 and type I interferons
production in dendritic cells in vivo. To do that, we directly sorted CD11c+ from the spleen of
infected WT and infected CARMA1 mice. Before sorting, one part of cells from spleen was
kept. Then, we detected the cellular production of IFNβ by RT-PCR. We found that the
production of INFβ in splenocytes from CAMRA3 deficient mice is nearly 10 folds less than
WT mice, while the difference goes up to nearly 20 fold in CD11c+ cells(Fig.36). It
suggested that CARMA1 contributed to VSV-induced the production of IFNβ in splenocyte
and CD11c+ cells.

3.26

CARMA1 deficiency did not affect VSV-induced the production of IL6
and IFNβ in BMDMs.

Next, we decided to study the role of CARMA1 in VSV-induced the production of IL6
and IFNβ in macrophage. To test the hypothesis, we cultured primary BMDMs isolated from
WT or CARMA1 deficient mice as previously described. Then, we infected the primary
cultures of BMDMs with VSV at MOI=3 and detected the production of IL6 and type I IFNs.
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We found the production of either IL6 or type I IFNs is comparable in BMDMs from both
types of mice after infection (Fig.37 A, B&C). Consistently, the activation of TBK1-IRF3
was also similar in BMDMs from both types of mice (Fig.37D). It suggested that CARMA1
deficiency did not affect VSV-induced the production of IL6 and IFNβ in macrophage.

3.27

Identification of CARMR3 binding partners by SILAC experiment.

To further characterize the CARMA3 signaling complex, we preformed SILAC
experiment to identify proteins that interact with CARMA3.Extraction from HEK 293T cells
expressing vector was labeled with ‘light’ isotopes, while extraction from HEK 293T cells
expressing CARMA3-FLAG was labelled with ‘heavy’ isotopes. After immunoprecipitation
with FLAG antibody conjugated beads, the precipitates from the heavy and light samples
were subject to SDS-PAGE and silver staining. The precipitates were excited from the gel
and digested with trypsin. The peptides were analyzed by nano liquid chromatography
tandem mass spectrometry(nanoLC-MS/MS). 512 different proteins were identified by
analyses of nanoLC-MS/MS (Figure 39B). 25 proteins enriched in the heavy sample were
considered as CARMA3 binding partners (Table 3). Among them, we found that CARMA3
has highest mass score, suggesting the success of the whole SILAC experiment (Figure 39C).
Gene ontology(GO) analysis was performed using Uniprot. We found that GO terms for
cellular process, metabolic process, biological regulation and single-organism process were
enriched in CARMA3 binding partners. We also found that CARMA3 interacts with Zinc
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finger CCCH-type antiviral protein 1(ZAP), which prevents infection by retroviruses (Gao,
Guo et al. 2002).
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Table 1 TLRs and some of their important ligands
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Table 2 The primers used in the experiments
Forward Primers

Backward Primers

Mouse ifnα

TGACCTCAACACTCAGCTCAA

AGGTGCCTGTATCTCTACCTG

Mouse ifnβ

CAGCTCCAAGAAAGGACGAAC

GGCAGTGTAACTCTTCTGCAT

Mouse il6

TCTATACCACTTCACAAGTCGGA

GAATTGCCATTGCACAACTCTTT

Mouse gapdh

AGGTCGGTGTGAACGGATTTG

TGTAGACCATGTAGTTGAGGTCA
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Table 3 The cellular binding partners of CARMA3.
Accession

Score

Mass

H/L

HEBP1_HUMAN

20

21234

1239

Description
Heme-binding protein 1 OS=Homo sapiens GN=HEBP1 PE=1 SV=1

NB5R4_HUMAN

18

59839

263.7

Cytochrome b5 reductase 4 OS=Homo sapiens GN=CYB5R4 PE=1 SV=1

PWP1_HUMAN

131

55793

198.2

ZN638_HUMAN

23

220488

161.3

DDX23_HUMAN

36

95524

151.8

EXOS5_HUMAN

57

25233

128.5

CD043_HUMAN

96

23849

96.63

EEPD1_HUMAN

16

62767

83.57

COR1B_HUMAN

57

54200

76.61

Periodic tryptophan protein 1 homolog OS=Homo sapiens GN=PWP1
PE=1 SV=1
Zinc finger protein 638 OS=Homo sapiens GN=ZNF638 PE=1 SV=2
Probable ATP-dependent RNA helicase DDX23 OS=Homo sapiens
GN=DDX23 PE=1 SV=3
Exosome complex component RRP46 OS=Homo sapiens GN=EXOSC5
PE=1 SV=1
UPF0534 protein C4orf43 OS=Homo sapiens GN=C4orf43 PE=1 SV=2
Endonuclease/exonuclease/phosphatase family domain-containing protein
1 OS=Homo sapiens GN=EEPD1 PE=1 SV=2
Coronin-1B OS=Homo sapiens GN=CORO1B PE=1 SV=1

TOP3A_HUMAN

15

113083

75.72

DNA topoisomerase 3-alpha OS=Homo sapiens GN=TOP3A PE=1 SV=1

RTC1_HUMAN

115

39311

57.1

PRP4_HUMAN

135

58412

46.47

ZER1_HUMAN

16

88612

44.74

CAR10_HUMAN

8141

115859

35.37

ZCCHV_HUMAN

125

101367

35.2

ASCC2_HUMAN

77

86306

25.51

K1C10_HUMAN

96

58792

16.78

Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6

RBM42_HUMAN

116

50749

12.38

SNUT1_HUMAN

403

90200

4.788

RNA-binding protein 42 OS=Homo sapiens GN=RBM42 PE=1 SV=1
U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1
PE=1 SV=1

UBF1_HUMAN

190

89350

4.37

P5CS_HUMAN

269

87248

2.726

XRN2_HUMAN

588

108513

2.442

RLA1_HUMAN

697

11507

2.366

FUS_HUMAN

236

53394

2.125

SFPQ_HUMAN

265

76102

2.068

RNA 3'-terminal phosphate cyclase OS=Homo sapiens GN=RTCD1 PE=1
SV=1
U4/U6 small nuclear ribonucleoprotein Prp4 OS=Homo sapiens
GN=PRPF4 PE=1 SV=2
Protein zer-1 homolog OS=Homo sapiens GN=ZER1 PE=1 SV=1
Caspase recruitment domain-containing protein 10 OS=Homo sapiens
GN=CARD10 PE=2 SV=2
Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens GN=ZC3HAV1
PE=1 SV=3
Activating signal cointegrator 1 complex subunit 2 OS=Homo sapiens
GN=ASCC2 PE=1 SV=3

Nucleolar transcription factor 1 OS=Homo sapiens GN=UBTF PE=1 SV=1
Delta-1-pyrroline-5-carboxylate synthase OS=Homo sapiens
GN=ALDH18A1 PE=1 SV=2
5'-3' exoribonuclease 2 OS=Homo sapiens GN=XRN2 PE=1 SV=1
60S acidic ribosomal protein P1 OS=Homo sapiens GN=RPLP1 PE=1
SV=1
RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1
Splicing factor, proline- and glutamine-rich OS=Homo sapiens GN=SFPQ
PE=1 SV=2
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Figure 1 TLRs in antivirus response. Viral PAMPs such as dsRNA, ssRNA,
RNA, CpG DNA
and viral proteins are recognized by different TLRs to trigger the activation
ion of NF-κB, AP1and IRF3/IRF7 to produce type I /III IFNs and proinflmmatory cytokines.. TLR1, TLR2 and
TLR4 are present on the cell surface, which recognize viral proteins. TLR3, TLR7, TLR8
and TLR9 are located in the endosome, which is required for the recognition of virus-derived
virus
dsRNA, ssRNA and CpG. Upon ligand recognition, TLRs recruit a serious of adaptor
proteins to activate downstream signaling pathways
pathways. Based on the different adapters, these
signaling pathways can be divided into two types, MyD88 and TRIF-dependent
dependent pathways.
TLR3 and TLR4 recruit TRIF
TRIF, while others TLRs with the exception
eption of TLR3 utilize MyD88.
MyD88
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Figure 2 RIG-I/MAVS signaling
ignaling pathway
pathway. After RNA virus infection, their RNA genomes
are recognized by RIG-I in the cytoplasm, where RIG-I changes its conformation and
exposes CARD domains. Then, tthe “active” RIG-I binds to and activates MAVS to form
prion-like aggregates on the outer membrane of mitochondrial, which serves as a platform in
activating downstream signaling pathways. For example, it activate
activates IKK complex. The
activated IKK complex phosphorylate
phosphorylates IκBα on its serine 32 and 36, which leads
lead to IκBα
degradation by 26S proteasome
proteasome. It frees NF-κB dimmer, which enters the nucleus to enhance
the production of inflammatory cytokines. On the other hand, the activated MAVS recruits
recruit
and activates NEMO-TBK1--IKKε complex, which phosphorylates and activates IRF3/7. The
activated IRF3/7 enters into the nucleus and play
plays an important role in the production of type
I IFNs.

63

Figure 3 IFNs signaling pathway
pathway. Based on different receptors, the IFNs are divided into
three different classes, type I, type II and type III IFNs. They share JAKs-STATs
STATs signaling
pathway to increase the transcription of IFN-stimulated genes (ISGs). In absence of virus, the
JAKs interact with the cytoplasmic domain of each IFN receptor subunits in an inactive form.
Upon ligand stimulation, receptor chains undergo conformational change to bring the kinase
domain of JAKs into close proximity, by which JAKs are autophosphorylated and
subsequently activated.
ed. Then, the “active” JAKs in turn phosphorylate the cytoplasmic part
of IFN receptors on some conserved tyrosine residues, which work as the docking sites for
STAT proteins. The receptor--recruitment of STAT proteins is essential for phosphorylation
phosphor
and activation of STAT proteins. After phosphorylation, STAT proteins form a homo-(type
homo
II
IFNs) or heterodimer (type I and type III IFNs)) and are released from IFN receptors. Then,
STAT proteins enter the nucleus to drive expression of ISGs.
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Figure 4 CARMA families of scaffold proteins. CARMA family has three proteins,
CARMA1, CARMA2 and CARMA
ARMA3. They share very similar structures with the same
domains.. These proteins all w
work as scaffold proteins in NF-κB
B signaling pathways. However,
they are expressed
ssed in different tissues. C
CARMA1 is expressed
ed in hematopoietic cells.
cells
CARMA2 is expressed in the placenta
placenta, skin and mucosal tissues. CARMA3 is expressed in
all non-hematopoietic
hematopoietic cells. Being activated, they will recruit partners, BCL10
10 and MALT1,
M
to form
rm a CBM complex to mediate NF
NF-κB activation by regulating IKK activities.
activities
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Figure 5 CARMA3 deficiency caused mice to be more resistant to the infection of H1N1
influenza virus. (A) Groups of 6-8 weeks WT or CAMRA3 deficient mice were intranasally
infected with H1N1 influenza virus at pfu=600. The change of mice bodyweight had been
measured daily until 2 weeks after virus infection. (B) WT, CARMA3 Het, CARMA3
deficient mice were intranasally infected with H1N1 influenza virus at pfu=500. Lungs from
different mice were harvested at 2 days after virus infection. The virus titer in lungs was
measured by the TCID50 assay with MDCKII cells.
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Figure 6 CARMA3 deficient mice had enhanced lung IFNβ production and decreased
level of serum IL6 after the infection of H1N1 influenza virus. Groups of 6-8 weeks WT
or CAMRA3 deficient mice were intranasally infected with H1N1 influenza virus at pfu=600.
(A) The serum was harvested 0, 3, 6 days from WT and CARMA3 KO mice. The serum IL6
from mice was measured by ELISA. (B) The lungs form mice were harvested 3 days after
infection. The mRNA was isolated from superior lobe of mice right lung using Trizol reagent.
The production of IFNβ was measured by qPCR using specific mouse ifnβ primers.
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Figure7 CARMA3 deficiency
eficiency caused mouse to be more resistant to VSV--GFP infection.
Groups of 6-88 weeks WT or CAMRA3 deficient mice were intranasally infected with VSV at
pfu=1×107. Spleens, brains and lung
lungs were harvested from mice at 2 days after infection.
The virus titer in different
rent tissues was measured by viral plaque assay. The pictures
picture of the
VSV-GFP
GFP in brains were taken by fluorescence microscope.
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mice had enhanced brain IFNβ production
roduction after VSV
Figure 8 CARMA3 deficient m
infection.6-88 weeks WT or CAMRA3 deficient mice were intranasally infected with VSV at
pfu=1×107. Serum and brains were harvested from the infected mice at one day after VSVGFP infection. (A) The serum IL6 and IFN
IFNβ were measured by ELISA. (B) The mRNA was
isolated from brains using Trizol reagent
reagent. The production of IFNβ and IL6 was measured by
qPCR using specific mouse ifn
ifnβ and il6 primers. * indicates P<0.05.
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Figure 9 The activation
ctivation of NF
NF-κB signaling pathway was reduced in CARMA3
deficient cells
ells after VSV Infection
Infection. (A)WT and CARMA3 deficient MEF cells were
infected with VSV at MOI=5.
I=5. At the different time points after virus infection, the nuclear
proteins were isolated as previously described. The NF
NF-κB activation was measured by
EMSA using 32P-labeled NF--κB and OCT-1 probe. (B) WT and CARMA3 deficient MEF
cells were infected with VSV at MO
MOI=5. At the different time points after virus infection, the
mRNA was isolated from cells using Trizol. The production of IL6 was measured by qPCR
with the specific mouse IL6 primers. (C) WT and CARMA3 deficient MEF cells were
infected with VSV at MOI as indicated. The infectious medium was replaced with fresh
medium at 1 hour after virus infection to get rid of uninfected virus
virus. The supernatant from
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both cell types was collected at 16 hours after virus infection. The protein amount of IL6 in
supernatant was measured by ELISA.
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deficient ccells had hyperactivation of TBK1-IRF3
IRF3 signaling
Figure 10 CARMA3-deficient
pathway and increased production
roduction of IFN-β after VSV Infection.(A)) and (B) Primary
CARMA3 Het and CARMA3 deficient MEF cells were infected with VSV at MOI=3. At the
different time points, the
he supernatant from cell was collected for the IFNβ analyses by
ELISA, whereas the cells were harvested for mRNA isolation by Trizol.. The production of
IFNβ was measured by both qqPCR using the specific mouse IFNβ primers and ELISA. (C)
Primary CARMA3 Het and CARMA3 deficient MEF cells were infe
infected
cted with VSV at
MOI=3. The activation of TBK1
TBK1-IRF3 signaling pathway was measured by immunoblotting
with specific p-TBK1 and p-IRF3
IRF3 antibodies. TBK1 and IRF3 were detected as a loading
control.
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eficiency contributed to reduction in viral yield in vitro after
Figure 11 CARMA3 deficiency
VSV infection. Primary WT and CARMA3 deficient MEF cells, Hela cells with control or
CARMA3 knockdown,, A431 cells with control or CARMA3 knockdown were infected with
VSV at MOI=10. At 1 hour after virus infection, the supernatant from each cell type was
replaced with the fresh medium to get rid of uninfected virus. The virus amount in
supernatant was measured using
sing viral plaque assay at 24 hours after infection.
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Figure 12 CARMA3-deficient
eficient MEF cells had less NF-κB activation and produced
p
less
IL6 after poly (I:C) transfection
ransfection.(A) and (B) Primary WT and CARMA3 deficient MEF
cells were transfected with 1µ
µg/ml poly(I:C) by lipofectamine 2000. At the different time
points after transfection, the
he supernatant from both cell types was collected for the ELISA
analyses, whereas the cells were harvested for mRNA isolation.. The production of IL6 was
measured both by qPCR using the specific mouse IL6 primers and ELISA.. (C) Primary WT
and CARMA3 deficient MEF cells were transfected with 11µg/ml poly (I:C)
I:C) by lipofectamine
2000. At the different time points after transfection, the nuclear proteins were isolated as
previously described. The NF
NF-κB activation was measured by EMSA using 32P-labeled NFκB and OCT-1 probe.
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Figure13 CARMA3-deficient
eficient MEF cells had hyperactivation of TBK1-IRF3
IRF3 signaling
pathway and produced more
ore type I IFNs after poly (I:C) transfection. Primary WT and
CARMA3 deficient MEF cells were transfected with 11µg/ml poly (I:C) by lipofectamine2000.
lipofectamine
At the different time points after transfection, tthe
he supernatant from both cell types was
collected for the ELISA analyses
analyses, whereas the cells were harvested for mRNA isolation. The
nuclear proteins were isolated as previously described. (A) and (C) The production of IFNβ
IFN
was measured both by qPCR
PCR using the specific mouse IFNβ primers and ELISA. (B) The
production of IFNα was measured by qqPCR using the specific IFNα primers. (D) The
activation of TBK1-IRF3
IRF3 sig
signaling pathway was measured by immunoblotting with specific
p-TBK1 and p-IRF3 antibodies
antibodies. TBK1 and IRF3 were detected as a loading control.
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Figure 14 CARMA3-deficient
eficient MEF cells produced less IL6 after the transfection
ransfection of 5'
ppp-dsRNA. Primary WT and CARMA3 deficient MEF cells were transfected with 1µg/ml
1
5’ppp-dsRNA or its control by lipofectamine2000.
2000. At the different time points after
transfection, the
he supernatant from both cell types was collected for the ELISA analyses,
whereas the cells were harvested for mRNA isolation. (A) and (B) The production of IL6 was
measured both by qPCR using the specific IL6 primers and ELISA.
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Figure 15 CARMA3-deficient
eficient MEF cells produced more IFNs after the transfection
t
of
5' ppp-dsRNA and its control
control. Primary WT and CARMA3 deficient MEF cells were
transfected with 1µg/ml 5’ppp
ppp-dsRNA or control by lipofectamine 2000.. At the different
time points after transfection, tthe
he supernatant from both cell types was collected for the
ELISA analyses, whereas the cel
cells were harvested for mRNA isolation. (A) The production
of IFNα was measured by qPCR
PCR using the specific IFNα primers. (B) and (C
C) The production
of IL6 was measured both by qqPCR using the specific IL6 primers and ELISA.
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Figure 16 BCL10-deficient
eficient MEF cells produced more IFNβ after VSV infection and the
poly (I:C) transfection.(A) BCL10 Het and BCL10 deficient MEF cells were infected with
VSV at MOI=3.At the different time points after infection, mRNA was isolated from cells.
cel
The production of IFNβ was measured by qqPCR using the specific IFNβ primers.
primers (B) BCL10
Het and BCL10 deficient MEF cells were transfected with 11µg/ml poly (I:C)
I:C) by
lipofectamine2000.
2000. At the different time points after infection, mRNA was isolated from
cells. The production of IFNββ was measured by qPCR using the specific IFNβ
IFN primers.
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eficient MEF cells had hyperactivation of TBK1-IRF3
IRF3 signaling
Figure 17 BCL10-deficient
pathway after VSV infection
infection. BCL10 Het and BCL10 deficient MEF cells were infected
with VSV at MOI=3. The activation of TBK1
TBK1-IRF3
IRF3 signaling pathway was measured by
specific p-TBK1 and p-IRF3
IRF3 antibodies. TBK1 and IRF3 were detected as a loading control.
BCL10 was detected as control to indicate cell types.
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Figure 18 BCL10-deficient
eficient MEF cells produced less IL6 after VSV infection and the
poly (I:C) transfection.(A)
(A) BCL10 Het and BCL10 deficient MEF cells were infected with
VSV at MOI=3. At the different time points after infection, mRNA was isolated from cells.
The production of IL6 was measured by qqPCR using the specific IL6 primers. (B) BCL10
Het and BCL10 deficient MEF cells were transfected with 11µg/ml by lipofectaminee2000.
lipofectamine
At
the different
fferent time points after infection, mRNA was isolated from cells. The production of
IL6 was measured by qPCR using the specific IL6 primers.
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Figure 19 A549 cells stably expressing CARMA3 shRNA or BCL10 shRNA had
ha
hyperactivation of TBK1-IRF3
IRF3 signaling pathway after VSV infection.A549
A549 cells stably
expressing control shRNA, CARMA3 shRNA or BCL10 shRNA were infected with VSV at
MOI=3. The activation of TBK1
TBK1-IRF3
IRF3 signaling pathway was measured by specific
specif p-TBK1
and p-IRF3 antibodies. TBK1 and IRF3 were detected as a loading control. BCL10 was
detected as control to indicate BCL10 knockdown efficiency.
.
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Figure 20 A549 cells stably expressing GFP shRNA,CARMA3
CARMA3 shRNA or BCL10
shRNA produced less IL6 and more IFN
IFNβ after VSV infection.A549
A549 cells stably
expressing GFP shRNA, CARMA3 shRNA or BCL10 shRNA were infected with VSV at
MOI=3. At the different time points after infection, mRNA was isolated from cells. The
production of IL6 and IFNβ was measured by qPCR using the specific IL6 and IFNβ primers

82

Figure 21 BCL10 deficiency
eficiency caused mice to be more resistant to VSV-GFP
GFP infection.
Groups of 6-88 weeks WT or BCL10 deficient mice were intranasally infected with VSV-GFP
at pfu=1×107. Spleens and brain
brains were harvested from mice at 2 days after infection. The
virus titer in different
rent tissues was measured by viral plaque assay.
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Figure 22 MALT1 deficiency did not impair VSV
VSV-induced
induced type I IFNs production.(A),
production.
(B) and (C) Primary WT and MALT1 deficient MEF cells were infected with VSV at
MOI=3.At the different time points after infection, mRNA was isolated from cells. The
production of IL6 and type I IFNs were measured by qPCR using the specific IL6, IFNα and
IFNβ primers.(D)
(D) Primary WT and MALT1 deficient MEF cells were infected with VSV at
MOI=3.At the different time points after infection, supernatant was isolated from cells. The
production of IFNβ were measured by ELISA.
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Figure 23 MALT1 deficiency did not affect VSV-induced NF-κB activation.
activation Primary
WT and MALT1 deficient MEF cells were infected with VSV at MOI=3
MOI=3.At
.At the different
time points after infection, the nuclear and the cytoplasmic proteins were isolated as
previously described. The NF
NF-κB activation was measured by EMSA using 32P-labeled NFκB and OCT-1 probe.. The cytoplasmic proteins were subject to immunoblotting using the
indicated antibodies.
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Figure 24 MALT1 deficiency did not affect VSV-induced
induced IRF3 activation.
activation Primary WT
and MALT1 deficient MEF cells were infected with VSV at MOI=3
MOI=3. At the different time
points after infection, the total cell lysates were isolated and subjected with immunoblotting
using indicated antibodies.
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nhibition of NF
NF-κB signaling pathway did not enhance
nhance the
Figure 25 The inhibition
phosphorylation of IRF3. Primary MEF cells were pretreated with NF
NF-κB inhibitor for half
an hour, which can block the translocation of p50. Then, primary MEF cells were infected
with VSV at MOI=3 for indicated time. Then, one part of cells was harvested for nuclear
protein extraction. Another part of cells was harvested for immunoblotting. The IRF3
activation was measured by specific pp-IRF3
IRF3 antibody. IRF3, TBK1 and ACTIN were
detected as a loading control. The NF
NF-κB activation was measured by EMSA.
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nhibition of new protein synthesis did not enhance the phosphorylation
hosphorylation
Figure 26 The inhibition
of IRF3. Primary WT and CARMA3 deficient MEF cells were pretreated with 10 ug/ml
cycloheximide (CHX) to block new protein synthesis. Then cells were transfected with 1
ug/ml poly (I:C) by lipofectamin
lipofectamine2000. At the different time points, the activation of IRF3
was measured by immunoblotting using specific p-IRF3 antibody. IRF3
3 and ACTIN were
detected as a loading control.
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Figure 27 CARMA3 and BCL10 work
worked downstream of MAVS, but upstream of
TBK1 or IKKε. (A) HEK 293 cells stably expressing control shRNA, CARMA3 shRNA,
BCL10 shRNA were transfected with the plasmids encoding MAVS-Flag
Flag with NF-κB-luc
NF
or
IFNβ-luc. At 24 hours after transfection, both NF-κB
B and IRF3 activation were measured by
luciferase assay. (B) HEK 293 cells stably expressing
ng control shRNA, CARMA3 shRNA or
BCL10 shRNA were transfected with the plasmids encoding TBK1-Flag
Flag with NF-κB-luc or
IFNβ-luc. At 24 hours after transfection, both the NF-κB
B and IRF3 activation were measured
by luciferase assay. (C) HEK 293 cells stably expressing control shRNA, CARMA3 shRNA,
BCL10 shRNA were transfected with plasmids encoding IKKε-Flag with NF-κB-luc
NF
or
IFNβ-luc. At 24 hours after transfection, the NF
NF-κB and IRF3 activation were
re measured by
luciferase assay. (D) After transfection
transfection,, cell lysates were collected and thereby, were
subjected with immunoblotting using indicated antibodies.
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Figure 28 CARMA3 and BCL10 interacted with MAVS,, when they are overexpressed
in HEK 293 cells. We overexpressed the plasmids encoding CARMA3-HA (A) or BCL10MYC (B) with MAVS-FLAG
LAG or RIG
RIG-I-FLAG in HEK 293 cells. At 24 hours after
transfection, MAVS or RIG-II was immunoprecipitated using anti-Flag-conjugated
conjugated beads.
The immunoprecipitated complex and cell lysates were subjected with immunoblotting
analysis with anti-FLAG antibody ((MAVS or RIG-I), anti-HA antibody (CARMA3) and
anti-MYC (BCL10)
BCL10) and other indicated antibodies.
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Figure 29 CARMA3 and BCL10 interacted with MAVS. (A)The immortalized CARMA3
deficient MEF cells were infected with lentivirus constructions encoding CARMA3-HA.
CARMA3
Then, we infected cells stably expressing CARMA3
CARMA3-HA
HA with VSV at MOI=3. At different
time points, cell lysates were immunoprecipitated using anti-HA- or control anti-IgGanti
conjugated beads. The immunoprecipated complex and cell lysates we
were
re subjected with
immunobloting analysis with anti-HA (CARMA3), anti-MAVS, anti-CARMA3,
CARMA3, anti-BCL10,
anti
anti-TUBULIN antibodies. (B) HEK 293 cells were transfected with 1 ug/ml poly (I:C) with
lipofectamine2000.
2000. At different time points, cell lysates were immunoprecipitated using antianti
BCL10-conjugated
conjugated or control anti
anti- IgG-conjugated
conjugated beads. The immunoprecipated complex
and cell lysates were subjected with immunoblotting analysis with anti-BCL10,
BCL10, anti-MAVS,
anti
anti-TRAF6 antibodies.
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Figure 30 CARMA3 and BCL10 competed with RIG-I in binding
inding with MAVS.MAVSMAVS
His and RIG-I-FLAG were overexpressed in presence of different doses of CARMA3-HA
CARMA3
or
BCL10-MYC in HEK 293 cells. At 24 hours after infection, cell lysates were precipitated
using Ni-NTA magnetic beads
eads. The precipitated complex and cell lysates were subjected
with immunoblotting analysis with anti-HIS (MAVS), anti-FLAG (RIG-I),
), anti-MYC
anti
(BCL10), anti-HA (CARMA3)
CARMA3) antibodies.
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Figure 31 The aggregation
ggregation of MAVS was required for NF-κB
B and IRF3 activation.
HEK 293 cells were transfected with plasmids overexpressing MAVS WT-FLAG
FLAG or MAVS
E26A-FLAG in presence of plasmids encoding NF
NF-κB-luc or IFNβ-luc.
luc. The NF-κB
NF
and
IRF3 activation were measured by luciferase assay. C
Cell lysates from transfected cells were
subjected with immunoblotting
ing analysis with anti-FLAG (MAVS WT and MAVS E26A),
E26A
anti-ACTIN antibodies.
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Figure 32 The interaction between CARMA3 or BCL10 with MVAS inhibited MAVS
to form prion-like structure. HEK 293 cells were transfected with plasmids overexpressing
RIG-I-FLAG and different dose of BCL10-MYC (A) or CARMA3-FLAG (B). 24 Hours
after transfection, mitochondrial and cell lysates were isolated from transfected cells. Then
mitochondrial were lysed and subjected with SDD-AGE to detect MAVS aggregates. Cell
lysates were subjected with immunoblotting with the indicated antibodies.
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Figure 33 CARMA3 deficiency in cells led to increased aggregation of MAVS after
virus infection. Primary WT and CARMA3 deficient MEF cells were infected with VSV at
MOI=3. At the different time points after infection, mitochondrial and cell lysates were
isolated from cells. Then, mitochondrial were lysed and subjected with SDD-AGE to detect
MAVS aggregates. Cell lysates were subject to immunoblotting with the indicated antibodies.
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Figure 34 Schematic models of CARMA3 and BCL10-mediating MAVS aggregation and
MAVS-mediating signaling pathway
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A

B

Figure 35 Compared to WT mice, CARMA1
CARMA1-deficient mice had less serum IFNβ and
IL6 after VSV infection. Groups of 66-8
8 weeks WT or CAMRA1 deficient mice were
intranasally infected with VSV at pfu=1
pfu=1×107. Serum or brains were harvested from the
infected mice at 24 or 48 hours after VSV
VSV-GFP infection. (A) The picturess of the VSV-GFP
VSV
in brains were taken by fluorescence microscope
microscope. (B) Serum IL6, IFNβ and IFNγ
IFN were
measured by ELISA.
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Figure 36 CARMA1 contributed to VSV
VSV-induced
induced the production of IFNβ in splenocyte
and CD11c+ cells.6-88 weeks WT or CAMRA1 deficient mice were intranasally
intranasal infected with
VSV at pfu=1×107. Serum, splenocyte and CD11c+ cells from splenocyte were harvested
from the infected mice at 24 hours after VSV-GFP infection. (A) The serum IFNβ
IFN and IL6
were measured by the corresponding ELISA kits. (B) The production of IFNβ
IFN from different
types of cells was measured by RT
RT-PCR.
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Figure 37 CARMA1 deficiency did not affect VSV-induced
induced the production of IL6 and
IFNβ in BMDMs. BMDM was harvested from different types of mice. WT and CARMA1
deficient BMDMs were infected with VSV at pfu=3. (A) The production of type I IFNs was
measured by RT-PCR.
PCR. (B) The production of IL6 was measured by RT
RT-PCR.
PCR. (C) Cell lysates
from infected cells were subject to immunoblotting
lotting using indicated antibodies.
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Figure 38 CARMA3 interacted with CASPASE-3, CASPASE-8 and capase-9.A431 cells
were infected with VSV at pfu=3. At different time points, cell lysates were subjected with
immunoblotting using indicated antibodies or immunoprecipitated using anti-CARMA3,
CASPASE8, CASPASE9 or CASPASE3 antibodies-conjugated beads. The
immunoprecipitated complexes were subjected with immunoblotting using indicated
antibodies.
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Figure 39 SILAC experiments to identify CARMA3’s binding partners
partner in cells. (A)
Workflow chart of the SILAC experiment. (B) Numbers of differential proteins and total
proteins identified. The pie chart show
showed percentages of differential proteins and total
proteins identified. (C) A representative spectru
spectrum assigned to CARMA3. (D) Gene
ontology(GO) analysis was performed using Uniprot.
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CHAPTER 4: DISCUSSION

Using WT MEF cells and CARAM3 or BCL10 deficient cells, we showed that CARMA3
and BCL10 played a positive role in RIG-I/MAVS-mediated NF-κB activation, whereas a
negative role in RIG-I/MAVS-mediated IRF3 activation. As a result, CARMA3 or BCL10deficient cells produced less IL6, but more type I IFNs than WT cells did, upon VSV
infection or specific ligands transfection. It was found that type I IFNs produced by cells
constituted the host first defense line against virus infection(Schneider, Chevillotte et al.
2014). Therefore, we found that CARMA3 deficient cells had less VSV replication after
infection. VSV and influenza mice model also confirmed the negative role of CARMA3 and
BCL10 during virus infection. Both in VSV and influenza mice model, CARMA3 deficient
mice had less virus titer than WT mice did. Furthermore, CARMA3 deficient mice had more
local IFNβ production after virus infection. Mechanistic study showed that CARMA3 and
BCL10 interacted with MAVS and directly regulated MAVS activities. CARMA3 and
BCL10 overexpression inhibited MAVS aggregation triggered by RIG-I overexpression.
Furthermore, MAVS more easily underwent aggregation in CARMA3 deficient cells,
compared to the WT cells. Together, these findings provided a strong evidence to show the
important role of the CARMA3 and BCL10 in orchestrating NF-κB and IRF3 activation.
Seasonal influenza virus outbreak in human results in about 3~5 million cases of severe
illness and around 500,000 deaths worldwide (Lozano, Naghavi et al. 2012). H1N1,
H2N2and H3N2 are the best-known IAVs currently circulating in humans. Additionally,
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avian influenza strains, such as H5N1 and H7N9, are emerging highly pathogenic strains
with significant pandemic potential and post a serious threat to global public health (Yen and
Webster 2009, Lam, Wang et al. 2013). Therefore, it is critical to study the host immune
response against IAV, which may facilitate the rational design of interference therapeutic.
It has been found that genetic diversity contributes to broad host responses and outcomes
upon IAV infection. Revealing genetic variations will provide the important information for
our understanding of antiviral immune responses. It is well known that genetic variations
between different mouse strains contribute to diverse phenotypic responses to IAV infection.
Therefore, it is reasonable to use mouse models to reveal genetic diversity for host
susceptibility to IAV infections and thereby, to identify many important genes associated
with host responses, for example, the landmark discovery of TLR4(Poltorak, He et al. 1998).
Recently, Ferris et al has been identified three novel quantitative trait loci (QTL) that may
contribute to the mice susceptibility for IAV infection, using incipient lines of mice with
highly genetical diversity. CARD10 that encodes CARMA3 was found within one of QTL.
However, the role of CARMA3 during IAV infection remains largely unknown. Previous
studies from our lab and others indicate the important role of CARMA3 in NF-κB signaling
pathway (Grabiner, Blonska et al. 2007, McAllister-Lucas, Ruland et al. 2007, Jiang,
Grabiner et al. 2011). However, the role CARMA3 in response to virus infection has not
been investigated before. In the study, we studied the role of CARMA3 and BCL10 in RIGI/MAVS signaling pathway for the first time, which suggests that CARMA3/Card10 may be
the genes contributing to the observed phenotype found in the study by Ferris et al (Ferris,
Aylor et al. 2013). It was found that influenza NS1 protein interacted with some PDZ103

containing proteins and inhibited the cellular anti-virus response, for example, the production
of IFNβ(Medina and Garcia-Sastre 2011). CARMA3 contains a PDZ domain and plays an
important role in anti-virus response. It would be interest to study whether CARAM3 is one
of host protein targeted by virus protein. Establishing these new paradigm will provide the
molecular basis for our future research to investigate whether the differential mutations or
SNP of CARMA3 (and its associated complex) contributes to the distinct response in human
patients to IAV (or other respiratory viruses) infection.
Our data suggested that CARMA3 and BCL10 played a positive role in RIG-I/MAVSmediated NF-κB activation, but a negative role in RIG-I/MAVS-mediated IRF3 activation.
Therefore, CARMA3 or BCL10 served as a “switch” to orchestrate NF-κB and IRF3
activation in RIG-I/MAVS signaling pathway, which was different from other regulators.
Most of them only had a unique role in both pathways. For example, the nucleotide-binding
domain and leucine-rich repeat containing family member 1(NLRX1) inhibited the
interaction between MAVS and RIG-I and thereby, inhibiting both NF-κB and IRF3
activation (Allen, Moore et al. 2011). Similarly, focal adhesion kinase(FAK) interacted with
MAVS on the outer membrane of mitochondrial in a virus-dependent manner and inhibited
the MAVS signaling(Bozym, Delorme-Axford et al. 2012). Another example is laboratory of
genetics and physiology 2 (LGP2), which serves a negative role in RLR pathway by
interfering the interaction between MAVS and downstream many E3 ligases (Komuro and
Horvath 2006, Tang and Wang 2009).
Similar to CARAM3 and BCL10, the linear ubiquitin assembly complex (LUBAC) also
plays a dual role in MAVS signaling. LUBAC consists of the E3 ligases HOIL-1L, HOIP and
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the accessory protein SHARPIN, which functions to stabilize the whole complex. After virus
infection, SHARPIN-deficient cells (cpdm) produced more type I IFNs, but decreased NF-κB
activation and less VSV replication. LUBAC induced linear ubiquitination of NEMO, which
led to NEMO’s association with TRAF3 and thereby, disrupted MAVS-TRAF3 interaction.
In this way, LUBAC served as a “switch” in both NF-κB and IRF3 signaling pathways by
regulating the linear ubiquitination of NEMO. The similarity in cellular response during virus
infection suggested that CARMA3 and LUBAC might share the similar mechanism to
regulate MAVS signaling. Interestingly, previous studies in our lab showed the CARMA3
physically interacted with NEMO and regulated IKK activities through NEMO-associating
ubiquitination. Additionally, linear ubiquitination of NEMO has been shown to play an
important role in activation of IKK complex in response to different stimulus (Belgnaoui, Paz
et al. 2012). It may explain why the NF-κB signaling pathway is partially defective in
CARMA3 deficient cells. More studied are needed to test the hypothesis. All studies
suggested the complicated regulating mechanisms in RIG-I/MAVS signaling pathways.
NF-κB signaling pathway can be activated by many viruses throughout different
mechanisms(Santoro, Rossi et al. 2003). However, it remains controversial that NF-κB
activity is beneficial to host. On one hand, NF-κB target genes play important roles in the
activation of the host immune and inflammatory response(Pahl 1999). For example, the NFκB activation induced the expression of many genes including many enzymes such as
cyclooxygenase 2, the inducible form of nitric oxide synthase, a variety of cytokines and
chemokines, receptors responsible for immune recognition, receptors involved in neutrophil
adhesion an transmigration across blood vessel walls, proteins required for antigen
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presentation and etc(Pahl 1999). Additionally, NF-κB activation does not required new
protein synthesis. Therefore, NF-κB activation is a rapid event that occurs within minutes
after virus infection, which constitutes the first host defense line against virus
infection(Hoesel and Schmid 2013). Consistent with this, mice with the deficiency of NF-κB
family members exhibit susceptible to virus infection. On the other hand, many viruses
evolve different strategies to hijack NF-κB, including HIV-1, HTLV-1, influenza virus,
hepatitis B and C virus, Herpes virus and etc(Santoro, Rossi et al. 2003). For example,
functionally important NF-κB-binding sites have been identified in the genome of several
viruses, including HIV-1, SV40 and different members of herpesvirus. These viruses utilize
NF-κB to drive the expression of many viral proteins (Sassone-Corsi, Wildeman et al. 1985,
Nabel and Baltimore 1987, Cherrington and Mocarski 1989, Rong, Libermann et al. 1992).
Additionally, the NF-κB is a transcription factor regulating the expression of many antiapoptotic genes such as members of the Bcl2 family, cellular inhibitors of apoptosis -1, 2,
TRAF proteins, and the FLICE-inhibitory protein(Hoesel and Schmid 2013). Therefore, NFκB activation improves cellular survival after virus infection, which is prerequisite for
completion of entire virus life cycle. Moreover, sometimes, aberrant NF-κB activation
sometimes caused chronic inflammation and leads to tissue damage, which is harmful to the
host. Therefore, virus-induced NF-κB activation is double-edged sword for both host and
pathogen survival.
During RNA virus infection, NF-κB was activated through both TLR-dependent and
MAVS/RIG-I signaling pathways. It was well established that CARMA3 is not required for
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TLR-induced NF-κB activation (Jiang, Grabiner et al. 2011, Pan and Lin 2013). In this study,
we found loss of CARMA3 impaired poly (I:C) and 5’ppp-dsRNA transfection induced NFκB activation. This suggests that CARMA3 and BCL10 play a specific role in by RIGI/MAVS signaling but not TLR-dependent NF-κB activation. However, in mice model, both
TLR and RIG-I-dependent signaling pathways contributed to NF-κB activation in immune
cells. This may explain why we don’t observe significant effect of CARMA3 deficiency in
systematic IL-6 mRNA at 24 hours post infection of VSV infection.
CARMA3 deficient cells enhanced the production of IFNβ but decreased NF-κB
activation after virus infection. It suggested that NF-κB did not play an essential role in IFNβ
production. Earlier studies revealed that NF-κB could bind to positive regulatory domains II
( PRDII) in IFN promoter and is required for the assemble of IFNβ enhanceosome. Single
base substitutions in κB sites in IFN promoter impaired inducibility of the IFN beta.
However, there is no endogenous evidence to show the essential role of NF-κB in the IFNs
induction at that time (Thanos and Maniatis 1995, Merika, Williams et al. 1998, Agalioti,
Lomvardas et al. 2000). Later, using p65-/- , p50 -/-p65-/- MFE cells, the researchers showed
that the production of type I IFNs was modest decreased after virus infection(Wang, Hussain
et al. 2007). Consistently, using p65-/- MFE cells, another two groups confirmed the
essential role of NF-κB in the early, but not late IFNs induction. It was found p65 deficient
cells produced less type I IFNs after virus infection at the early time points, but not later time
points (Basagoudanavar, Thapa et al. 2011). One reasonable explanation is the activation of
IRF3 or IRF7. The essential role of IRF3 and IRF7 has been demonstrated using mouse
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model. More importantly, high activation of IRF3 only sufficiently induced the type I IFNs in
p65-/- MEF cells (Wang, Basagoudanavar et al. 2010, Basagoudanavar, Thapa et al. 2011).
In our studies, the NF-κB activation was decreased in CARMA3 deficient MEF cell, whereas
IRF3 activation was enhanced, which resulted in the increased production of type I IFNs.
CARMA3 and BCL10 may provide a better drug target, considering their dual role in
MAVS signaling. On one hands, drugs targeting CARMA3 and BCL10 manipulate the
production of type I IFNs, which inhibit virus proliferation by targeting proteins or functions
involved in virus life cycle. On the other hands, it suppresses the inflammation by inhibiting
NF-κB activation, which is double-edged sword during virus infection. Therefore, the
balance between NF-κB activation and antiviral response is key events for host to survive.
Drugs targeting CARMA3 and BCL10 may meet the scenario.
Currently, the prevail view is that the “activated” MAVS undergoes self-aggregation to
form prion-like structure, which severs as a platform on mitochondrial to recruit many E3
ligases, including TRAF6, TRAF2, TRAF5 and LUBAC. These E3 ligases play essential
roles in activating both NF-κB and IRF3. Therefore, the MAVS polymerization is essential
for both pathways (Hou, Sun et al. 2011). There is something in common between our model
and prevailing model. We also confirmed the importance of MAVS self-aggregation in both
pathways by luciferase assay using plasmids encoding WT MAVA and MVAS E26A. The
difference between two models lies in different state of MAVS aggregates. Our model shows
that MAVS self-aggregation was a dynamic process. Less aggregated MAVS interacts with
CAMRA3 and BCL10, which is important for NF-κB activation and blocks the formation of
more aggregated MAVS. After CARMA3 is cleaved, the MAVS undergoes further
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aggregation to activate both the IRF3 and NF-κB. Compared to previous model, our model
can explain that NF-κB activates prior to IRF3 activation. Also, 1M GA can block the IRF3
activation, but cannot block the degradation of IKBα. Furthermore, the data from Liu’s paper
also supported our model. Using agarose gradient assay, the researchers found the activated
MAVS exited in complex with different molecular weight. It suggested that MAVS had
different aggregated status (Hou, Sun et al. 2011). Additionally, there is IKKβ only in the
complex with low molecular weight.
CARMA family has three members, CARMA1, CARMA2, CARMA3, which share
similar domains structure but with different tissue distribution(Jiang and Lin 2012). It
suggests that CARMA1 and CARMA3 may regulate the same signaling pathway in a similar
manner but in different tissues (Grabiner, Blonska et al. 2007). Consistent with this, previous
studies showed that CARMA1 was the counterpart of CARMA3 in hematopoietic cells
(Matsumoto, Wang et al. 2005). However, we surprisingly found that CARMA1 played a
positive role in VSV-induced the production of both IL6 and IFNβ in vivo, which is different
form CARMA3. CARMA1 deficient mice had less serum IL6 and IFNβ than WT mice did at
24 hours after virus infection. In contrast, the level of serum IFNγ is similar between WT and
CARAM1 mice. While in CARMA3 deficient mice, the level of serum IL6 and IFNβ is
comparable with WT mice. It is well known that IFNs with their receptors are important for
host immune system against virus infection(Schneider, Chevillotte et al. 2014).Therefore,
CARMA1 contributed to the innate immunity against virus infection by regulating the
production of IFNβ.
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Previous studies mainly focused on revealing the role of CARMA1 in NF-κB
activation in T cell or B cells and thereby, in adaptive immunity. Therefore, it would be
interesting to study the role of CARMA1 in innate immunity. Dendritic cells would be a
candidate cell type used in our future studies, since they are the main IFN producing cells in
vivo after RNA virus infection(Colonna, Krug et al. 2002). Additionally, using the CD11c+
cells from spleen from WT and CARAM1 deficient mice, we found that VSV-induced IL6
and IFNβ production is decreased in CARMA1 deficient cells. It suggested that CARMA1
contributed to the production of these two cytokines in dendritic cells. More studies are
needed to study how CARMA1 contributed to observed phenotype. We will investigate the
role of CARMA1 in RIG-I-and TLR-dependent signaling pathway in dendritic cells,
respectively, since RIG-I and TLR system exert antiviral response in a cell type dependent
manner. For example, RIG-I is required for the production of type I IFNs in conventional
dendritic cells (DCs). In contrast, plasmacytoid DCs utilized the TLR system rather than
RIG-I for viral detection (Kato, Sato et al. 2005). It may explain that CARMA1 plays a
positive role in VSV-induced the production of cytokines, which is different from CARMA3.
Using bone marrow derived-macrophages, we found that CARMA1 deficiency did
not affect VSV-induced the production of IL6 and IFNβ in macrophage, since the production
of two cytokines is similar in cells from WT or CARMA1-deficient mice. Consistent with
this, the activation of TBK1-IRF3 was also similar in BMDMs from both types of mice. One
possible explanation for this observation is that other CARD domain containing proteins may
substitute the CARMA1’s role in macrophage. CARD9 may be the best candidacy. CARD9
is structurally similar to CARMA family members with N-terminal CARD and a CC domain.
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However, it lacks the C-terminal MAGUK domain, which is important for plasma membrane
localization(Blonska and Lin 2011). Without MAGUK domain, CARD9 may reside in
cytosol and be recruited to signaling complex after activation. Different from CARMA
family proteins, the CARD9 expression seems to be restricted to myeloid cells such as
macrophages, dendritic cells and neutrophils(Bertin, Guo et al. 2000, Gross, Gewies et al.
2006). More recent studies have revealed the important role of CARD9 in RIG-I/MAVS
signaling pathway (Poeck, Bscheider et al. 2010). The authors found that CARD9-deficient
myeloid cells produced less IL6 and pro-IL-1β after transfection of RIG-I ligands or dsRNA
virus infection. Since the transcription of il6 and pro-IL-1β are controlled by NF-κB
signaling pathway, CARD9 may contribute to RIG-I-mediated NF-κB activation in
macrophage, which may substitute CARMA1’s role in the same signaling pathway (Poeck,
Bscheider et al. 2010).
Although serum IFNβ level is decreased in CARMA1 mice after VSV infection, the
virus burden in brains of CARMA1 deficient mice is similar to that of WT mice (Fig.35
A&B). In contrast, the virus burden in brains of CARMA3 deficient mice is less than that of
WT mice, while serum IFNβ level is comparable with mice (Fig8 A&B).These dates suggest
that serum IFNβ level does not correlate with VSV spread in brains. It may due to the fact
that the peripheral type I IFN would not easily go through blood brain barrier (BBB) to reach
brain (Detje, Lienenklaus et al. 2014). Besides, VSV spread in brain is efficiently arrested by
the local type I interferon (Detje, Meyer et al. 2009). Consistently, using qPCR, we can
detect more production of IFNβ in brain from CARAM3 deficient mice than that from WT
mice (Fig8 B), which decreased VSV spread in brain.
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There are limitations in the present study. Firstly, our experiments relied too much on
primary MEF cells to study antivirus response, although MAVS and RIG-I had wide tissue
distribution and shared a similar signaling pathway to activate NF-κB and IRF3 in many
types except plasmacytoid dendritic cells (Sun, Sun et al. 2006). It is well known that cellular
antiviral response is determined by both the cell type and virus type. For example, VSV is
capable of infecting many different types of cells, whereas the main targets of influenza virus
are epithelial cells. More importantly, the majority of data generated using VSV may not be
extended to IAV. In this case, we will isolate and differentiate primary lung and airway
epithelial cells (LECs) from WT and CARMA3 deficient mice, and then infect cells with
IAV or VSV to measure NF-κB by and TBK1/IRF3 activation as well as the production of
IFNβ and IL6. Also, we are going to detect virus replication in WT and CARMA3 KO cells
and the sensitivity of two cell types to virus infection.

Our study suggests a dual role of the CARMA3-BCL10 complex in RIG-I/MAVSmediated NF-κB and IRF3 activation and elucidates the mechanism of how CAMRA3 and
BCL10 regulate MAVS signaling, which may facilitate the development of the
corresponding methods to manipulate the antivirus response and the production of
inflammatory cytokines.
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CHAPTER 5: FUTURE DIRECTION AND PERSPECTIVE SECTION

As a scaffold protein, CARMA3 contains multiple domains for protein-protein
interaction including CARD domain and PDZ-domain. Here we found that CARMA3
interacted with MAVS and negatively regulated the formation of MAVS aggregates and
IRF3 activation. It would be interesting to know which domains and/or residues are required
for the interaction between CARMA3 and MAVS and thereby, are important for mediating
RIG-I/MAVS signaling. Fine mapping of CARMA3 will provide insights for further studies
and drug development. Since there is no cure and effective vaccine available for many RNA
viruses, it will be important to develop medicine that help reduce inflammation while
enhance anti-viral response. CARMA3 is such a good target that meets both criteria.
Furthermore, it was interesting to find that CARMA3 protein level was gradually
turned over or CARMA3 was cleaved during VSV infection, which may serve as a feedback
to enhance the IRF3 activation, and meanwhile, to shut down NF-κB activation. The
presence of CARMA3 during early time of infection inhibited the function of MAVS in
mediating IRF3 activation. With CARMA3 gradual turnover or cleavage, this inhibitory
effect weakens and IRF3 activation is activated. Therefore, in the absence of CARMA3 from
the beginning of virus infection, IRF3 can be activated at greater level and maybe at earlier
time points as well. Further studies are necessary to address what causes this CARMA3
turnover or cleaved and how? CASPASE 8 might be a potential protein cleaving CARMA3,
since we found that CASPASE8 interacted with CARMA3. Additionally, we identified one
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cleaved band using antibody targeting C-terminal of protein. Using antibody targeting both
ends of the protein, we identified two cleaved bands. It suggested the cleaved site was
located in the middle of proteins. Then, based on sequence analyses, we found there was one
potential CASPASE8 cutting site in the middle of CARMA3. More studies are needed to
study the role of CASPASE 8 in the cleavage of CARMA3, since it may reveal the role of
CASPASE 8 in RIG-I/MAVS signaling pathways.
By SILAC experiment, we identified 25 potential CARMA3 binding partners. Among
them, ZAP aroused our great interests. ZAP was initially discovered by screening genes that
prevent retrovirus infection in a cDNA library. Later, the functional studies of ZAP protein
revealed that the expression of ZAP inhibited the expression of viral genes in the cytoplasm
without affecting the level of nuclear mRNAs (Gao, Guo et al. 2002). The following studies
showed that ZAP directly interacted with viral mRNA at ZAP-responsive elements through
its four CCCH zinc-finger motifs(Jeong, Kim et al. 2010). Then, it recruited polyA-specific
ribonuclease PARN, 3’-5’ exoribonuclease complex, DCP1-DCP2 decapping complex to
degrade the RNA body from both 5’ and 3’-ends(Zhu, Chen et al. 2011). ZAP targeting
viruses includes HIV-1, moloney and murine leukemia virus, xenotropic MuLV-related virus,
ebola virus, marburg virus, sindbis virus and Ross river virus. Among them, HIV-1 and
Ebola also were RIG-I target viruses (Spiropoulou, Ranjan et al. 2009, Wang, Wang et al.
2013). As a CARAM3 binding partner, ZAP might work together with CARAM3 in the RIGI/MAVS signaling pathway. More studies are needed to test this hypothesis.
By GO analysis, we found that most of CARMA3 binding partners were involved in
metabolic process (Figure 39D). Additionally, both CARMA3 and BCL10 reside in the
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mitochondrial (Figure 32&33). The mitochondrial have been shown to play an important
role in metabolic pathways including carbohydrate metabolism, fatty acid oxidation, urea
cycle (Demine, Reddy et al. 2014) . Therefore, in future studies, we are going to investigate
the role of CAMRA3 in these metabolic pathways.
In this study, we found that CARMA3 deficient mice showed reduced disease
symptoms and/or better survival, when challenged with VSV or influenza. These viruses
represent negative, single-stranded RNA viruses. It will be interesting to see if CARMA3
indeed play a general effect in response to other RNA viruses. And can this expend to DNA
viruses?
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